


Department of Biochemistry and Chemistry

School of Agriculture, Biomedicine and Environment

Scientists at the forefront of knowledge in research areas including synthetic, organic, inorganic and analytical chemistry, molecular, cellular and structural biology, fundamental and applied biochemistry in microbes, plants and animals, as well as biomedical applications in human health and disease



Contents

School of Agriculture, Biomedicine and Environment / 3

Department of Biochemistry and Chemistry / 4

Research Centres / 6

Biomedical and Environmental Sensor Technology (BEST) Research Centre / 7

Research Centre for Extracellular Vesicles / 8

Research Groups / 9

Cancer Biology, Cell Polarity, and Tissue Architecture Group (Patrick Humbert) / 10

Cell Death and Survival Group (Doug Fairlie and Erinna Lee) / 11

Cell Signalling and Rare Metabolic Disease Group (Travis Johnson) / 12

Computational Chemistry Group (David Wilson) / 13

Dead Cell Clearance and Infection Group (Kha Phan) / 14

Dying Cell Clearance and Disassembly Group (Ivan Poon) / 15

Electrochemical Sensing Group (Conor Hogan) / 16

Exosomes, secretome and systems biology (Suresh Mathivanan) / 17

Fluorescence Chemical Biology Group (Yuning Hong) / 18

Immunometabolism and Macrophage Biology Group (Katrina Binger) / 19

Inflammation and tumour progression group (Mark Hulett) / 20

Inventing Chemistry Group (Jason Dutton) / 21

La Sense Research Group (Saimon Silva) / 22

Materials design using AI and machine learning (Dave Winkler) / 23

Medicinal Inorganic Chemistry and Luminescent Sensors (Peter Barnard) / 24

Mitochondrial Proteostasis Lab (Kaye Truscott) / 25

Molecular Self-Assembly and Nanoarchitecture Group (Adam Mechler) / 26

Multifunctional and Advanced Interfaces Group (Wren Greene) / 27

Muscle Biochemistry Group (Robyn Murphy) / 28

Neurodegeneration EV Biology and Biomarker Group (Lesley Cheng) / 29

Neurodegeneration and Neurorepair Group (Jacqueline Orian) / 30

Optical Spectroscopy of Atmospheric, Astrochemical and Biological molecules (Evan Robertson) /

31 Peptide Chemical Biology Group (Wenyi Li) / 32

Protease Biology Group (Lakshmi Wijeyewickrema) / 33

Structural Biology and Bacterial Pathogenesis Group (Begoña Heras) / 34

Translational Biology Group (Hamsa Puthalakath and Michael Foley) / 35

Vascular Cell Death, Clearance and Inflammation Group (Amy Baxter) / 36

Vascular Therapeutics and Regeneration Group (Kazuhide Shaun Okuda) / 37

Viral and Structural Immunology Group (Stephanie Gras) / 38

About La Trobe University / 39

About Victoria and Melbourne / 40

Cover Photo: Immunofluorescence microscopy of the cytoskeletal network in human PC3 prostate cancer cells. Photo credit: Guneet Bindra, PhD student Hulett lab

About the School of Agriculture, Biomedicine and Environment

The School of Agriculture, Biomedicine and Environment is one of the largest in the University, with more than 250 continuing and fixed term staff across multiple campuses. The School has seen significant growth in both research and teaching revenue. Staff in the School currently generate a significant proportion of the University's teaching revenue and research income, and supervise more than 230 higher degree research students. The School is responsible for 7 undergraduate degree courses at the main Bundoora campus in Melbourne, and our regional campus at Albury-Wodonga. It is a leader in teaching innovation and student satisfaction within the university.

The School undertakes teaching and research across a broad range of disciplines, including: Agriculture, Botany, Soil Science, Animal Science, Plant Science, Ecology, Environmental Geoscience, Evolution and Genetics, Conservation Biology, Zoology, Neurobiology, Microbiology, Physiology, Pathophysiology, Pharmacology and Anatomy, Biochemistry, Chemistry and Cardiovascular Physiology.

The 4 departments in the School are:

- Baker Department of Cardiovascular Research, Translation and Implementation
- Biochemistry and Chemistry
- Ecological, Plant and Animal Sciences
- Microbiology, Anatomy, Physiology and Pharmacology

The School of Agriculture, Biomedicine and Environment has recognised research expertise in biological, biomedical, environmental, molecular and chemical sciences. Our outstanding research environment gives academics access to the facilities and infrastructure needed to make significant discoveries.

We work collaboratively with our partners in industry, clinical organisations, philanthropy and government to achieve research outcomes that have a positive impact on the communities we serve.



We bring together the right capabilities, manage projects efficiently, act with integrity, and turn research results into translational outcomes.

Our contribution aligns with La Trobe's research themes: Healthy people, families and communities; Resilient environments and communities; and Understanding and preventing disease.

The School of Agriculture, Biomedicine and Environment research environment is dynamic and growing, and includes these major research centres:

- Centre for Cardiovascular Biology and Disease (collaboration with the Baker Heart and Diabetes Institute)
- Research Centre for Extracellular Vesicles
- Centre Research Biomedical and Environment Sensor Technology (BEST)
- Research Centre for Future Landscapes (collaboration with the Arthur Rylah Institute of DELWP)
- Centre for Freshwater Ecosystems
- Research Centre for Applied Alpine Ecology

Many of our staff are members of one of the University's flagship Institutes:

- La Trobe Institute of Sustainable Agriculture and Food (LISAF)
- La Trobe Institute for Molecular Science (LIMS)

Or research centres:

- ARC Centre of Excellence in Plants for Space
- ARC Industrial Transformation Research Hub for Protected Cropping
- Industrial Transformation Research Hub for Molecular Biosensors at Point of Use (MOBIUS).
- Mallee Regional Innovation Centre (MRIC)(a joint venture with The University of Melbourne)



Professor Robyn Murphy
Dean, School of Agriculture,
Biomedicine and Environment


Department of Biochemistry and Chemistry

The Department of Biochemistry and Chemistry consists of more than 75 continuing and fixed-term academic staff, including six NHMRC Investigators (1x L2, 1x L1, 4 x EL1), two ARC Future Fellows, two ARC DECRA Fellows, one Moderna, one Victorian Cancer Agency Research Fellow, and one National Heart Foundation Fellow.

We teach over 2000 students enrolled across undergraduate and master's subjects. We take great pride in providing a friendly and supportive environment, taking particular care to ensure a positive experience for our students. We oversee La Trobe's courses in undergraduate Biomedicine, Masters in Biochemistry and Biotechnology, and Masters in Biotechnology Management, as well as teach in to La Trobe's undergraduate Science course and offer fully online subjects through Open Universities Australia. A number of our teaching staff have been recognized as Fellows of the UK's Higher Education Academy and have received university and national awards for innovation and excellence in curriculum design and delivery.

Our department trains graduates who are ready to take up a diverse range of job opportunities, with potential careers in research institutes, manufacturing and chemical industries, pharmaceutical and biotech companies, government departments and agencies, as well as pathology laboratories and hospitals.

The Department has a dynamic Higher Degree by Research (HDR) program that reflects the multidisciplinary interests of the staff. We are currently training 80 PhD and Masters students and 20 Honours students from Australia and overseas.



Research carried out in the Department is world leading and focusses on some of today's biggest challenges in biomedicine and biotechnology. Staff and postgraduate students research molecular structure and design, the molecular basis of human health and disease, and have a strong focus on translating our fundamental discoveries into new diagnostics and treatments. Indeed, over the past few decades our department has several embedded biotech companies including Hexima Ltd, Adalta Ltd, VivaZome Therapeutics Ltd, and Immunexus Therapeutics Ltd.

Our breadth of expertise and co-location in the world-class facility of the La Trobe Institute for Molecular Science (LIMS) creates opportunities for new discoveries in molecular science and the important health challenges of cancer, neurodegenerative diseases, infection and immunity, cardiovascular disease, and rare diseases. Through this research, members of the Department are key contributors to La Trobe's new Research Theme Understanding and preventing disease.

The Department's research activities also underpin La Trobe Universities rating of '5-well above world standard' in latest round of Excellence in Research Australian (ERA) in the broad areas of Chemistry and Biology, and in the discipline areas of Analytical Chemistry, Biochemistry and Cell Biology, Medicinal and Biomolecular Chemistry. The department has also contributed to similarly high ratings in areas of Microbiology and Neuroscience.

The Department's research environment is dynamic and multidisciplinary and includes strong collaborative ties with world-renowned medical research institutes such as The Olivia Newton John Cancer Wellbeing Centre, and The Baker Heart and Diabetes Institute, as well as facilities such as the Australian Synchrotron. We are home to these major research centres:

- Research Centre for Extracellular Vesicles
- Centre Research Biomedical and Environment Sensor Technology (BEST)

We are also the founding department for LIMS (the La Trobe Institute for Molecular Science).

Research Centres

- Biomedical and Environment Sensor Technology (BEST) Research Centre
- Research Centre for Extracellular Vesicles

Biomedical and Environment Sensor Technology (BEST) Research Centre

The Biomedical and Environmental Sensor Technology (BEST) Research Centre holds a goal of improving the quality of life for people within our society. We aim to do this by developing new and better sensor technology. Sensor technology is an important research field. Chemical sensors and biosensors provide essential information about our chemical and biological environment. In doing so, they enable better quality of life through accurate and personalized medical diagnoses, efficient energy use, better industrial processes, safer and more ethical food, and a cleaner environment. Because sensor technology is a very broad topic, we have brought together a range of varied expertise from academia and industry. Through collaboration, we can create better sensors, and improve quality of life. The BEST Centre is focused on developing the next generation of sensor technology. Our research covers a broad range of areas from health and disease diagnosis to sensing for transport and energy networks.

Nanofabricated molecular imaging devices for disease diagnostics and environmental monitoring

Development of nanostructured microscope slides to detect the presence of diseased or abnormal cells (e.g. cancer or MS) and also to monitor changes in chemical composition at the nanoscale through combination with microfluidics.

Optical nanoscopy of lipid membranes

Using the newly developed La Trobe near-surface optical microscope we will continue to develop quantitative optical microscopy methods for characterising the composition and topography of cell membranes.

Fluorescent reporters for sensing and imaging proteostasis dysfunction

Developing novel fluorescent probes to quantify proteostasis, which ensures proper protein folding and function, and prevents accumulation of unfolded and misfolded proteins. Methods to quantify proteostasis capacity and the impact on individual proteins on a global scale in cell are currently lacking. Therefore, we are developing novel fluorescent probes which are being tested by collaborators in the Royal Melbourne Hospital, and the Nationwide Children's Hospital, Ohio, USA.



Nanoscale phase contrast imaging combined with metal-conjugated antibody detection

X-ray fluorescence measurements conducted at the Australian synchrotron using metal-conjugated antibodies permit molecular tracking with a much larger parameter space than current optical approaches. When combined with ultrasensitive phase contrast mapping (ptychography) this project will deliver a new X-ray based technique for molecular imaging in-situ which simultaneously characterises the tissue microstructure.

Functional heterobimetallic probes for sensing sugars

Development of new molecular organometallic probes for sensing biologically important carbohydrates and glycalated proteins. This project will result in improved methods for diagnosis and management of diseases associated with these markers such as diabetes and Alzheimer's disease.

Innovative approaches to sensing based on synthetic biology

The rapid detection of contaminants at low concentrations is essential to prevent the spread of nefarious substances through the environment. Sensitivity and specificity of detection is vital to prevent environmental and economic damage. Synthetic biology provides a systematic approach to rationalising molecular pathways within microbes allowing the programming desired outputs from specific inputs such as heavy metals.

New miniaturised instruments for point-of-care immunodiagnostic applications

This project epitomizes in many ways the principles of BEST. A collaboration which

seeks to translate some of the high impact fundamental science emerging from the chemistry discipline in recent years, by leveraging expertise in the physics discipline in instrument development; and the largely untapped resource comprising the electronics and product design capabilities of the School of Molecular Sciences workshop. Underpinned by solid market research, this project will provide a new platform to showcase next generation diagnostics.

Mobile phone-based point-of-care diagnostics

Detection of Sepsis and Malaria biomarkers utilising only a cheap disposable sensor strip and the built-in audio and camera of a mobile phone to carry out sophisticated electrochemical and luminescence-based analyses. More broadly, making inexpensive, quantitative sensors for medical sensing applications to make chemical and biochemical analysis, usually confined to the lab, widely available through similar "instrument free" analysis.

New Electrochemiluminescence based detection strategies

Develop novel supramolecular assemblies that exhibit electrochemically-sensitized luminescence (ESL) by coupling metal complex donors to either luminescent nanoparticles or fluorescent proteins. These assemblies are predicted to have unique sensing properties using simple analytes and bio-markers.

Director:

Dr Saimon Moraes Silva
(S.MoraesSilva@latrobe.edu.au)

Research Centre for Extracellular Vesicles

The La Trobe Research Centre for Extracellular Vesicles (RCEV) integrates a diverse group of internationally recognised researchers sharing a major interest in the study of extracellular vesicles (EVs). Our team explores EVs and their critical role in cell and tissue communication. We are based in the School of Agriculture, Biomedicine and Environment. Our team has expertise in the isolation and analysis of extracellular vesicles from cells, biofluids and tissues and next generation deep sequencing of EV cargo (especially small RNAseq and available workflow/technology).

We provide our national and international collaborators and industry partners a unique hub, for research, learning and engagement. Our objective as a research centre is to work with national and international groups to study how and why EVs mediate cell-cell communication. We hope to explore ways of harnessing this power.


We do this by:

- building an Australian Research Centre encompassing academic researchers, industry partners and educational activities to gain knowledge about EVs in intercellular communication.
- spearheading a multidisciplinary, collaborative program of research to understand, monitor and exploit EVs in the normal and disease processes of all organisms, from plants to humans.

We are studying EVs to advance our understanding of their novel role in the fundamental cellular processes of cell to cell communication and potential biological applications. In the future, we will translate results from these basic biological studies to outcomes with real world impact. Our ultimate aim is to develop methodologies to use EVs for diagnostic purposes in medicine and agriculture and as tools to deliver therapeutics in humans, animals and plants.

New methodologies

We are developing new, rapid and rigorous methodologies for EV isolation and characterisation. This enables extraction and functional analysis of distinct EV subtypes from biofluids and clinical



White blood cell (monocyte) undergoing programmed cell death (apoptosis). Photo credit: Georgia Atkin-Smith and Ivan Poon

samples, quantification of the biophysical, genetic, protein, and lipid makeup and how this exerts functional changes in target tissues.

Vesicle biogenesis

Our researchers are also dissecting vesicle biogenesis - the cellular pathways that regulate how different EVs, called exosomes, microvesicles and apoptotic vesicles are formed and released by cells. Once we understand this, it may be possible to manipulate different stages in a targeted way and control cell to cell communication.

Biomarkers

EVs represent a reservoir of new biomarkers for pathogenesis and susceptibility to disease and as drug delivery vehicles for novel therapeutics. We are studying novel and specific disease associated biomarkers in EVs isolated from clinical samples, including cancer, neurodegenerative diseases and the early stage of pregnancy.

Host-pathogen communication

We are also studying the role of EVs in host-pathogen communication during fungal and bacterial pathogenesis and in the transfer of antibiotic resistance.

Director: Professor Ivan Poon (I.Poon@latrobe.edu.au)

Deputy Directors:

Dr Lesley Cheng; Dr Pamali Fonseka.

Strategic Partners:

The University of Adelaide
Baker Heart and Diabetes Institute
Curtin University
The Florey Institute of Neuroscience & Mental Health
Garvan Institute of Medical Research
Hudson Institute of Medical Research
The University of Melbourne
Monash University
Murdoch Children's Research Institute
University of Sydney
QIMR Berghofer Medical Research Institute
University of Queensland
University of Technology Sydney
Walter and Eliza Hall Institute of Medical Research
University of Western Australia
Aalborg University, Denmark
University of Auckland, NZ
Beijing Genomics Institute, China
University College London, UK
University of Gothenburg, Sweden
Hallym University, South Korea
University of Hohenheim, Germany
Kings College London, UK
University of Oxford, UK
Institute for Systems Biology, Seattle, USA
University of Texas, USA
University of Virginia, USA
University of Utrecht, Netherlands

Research Groups

Cancer Biology, Cell Polarity, and Tissue Architecture Group (Patrick Humbert) / 10
Cell Death and Survival Group (Doug Fairlie and Erinna Lee) / 11
Cell Signalling and Rare Metabolic Disease Group (Travis Johnson) / 12
Computational Chemistry Group (David Wilson) / 13
Dead Cell Clearance and Infection Group (Kha Phan) / 14
Dying Cell Clearance and Disassembly Group (Ivan Poon) / 15
Electrochemical Sensing Group (Conor Hogan) / 16
Exosomes, secretome and systems biology (Suresh Mathivanan) / 17
Fluorescence Chemical Biology Group (Yuning Hong) / 18
Immunometabolism and Macrophage Biology Group (Katrina Binger) / 19
Inflammation and tumour progression group (Mark Hulett) / 20
Inventing Chemistry Group (Jason Dutton) / 21
La Sense Research Group (Saimon Silva) / 22
Materials design using AI and machine learning (Dave Winkler) / 23
Medicinal Inorganic Chemistry and Luminescent Sensors (Peter Barnard) / 24
Mitochondrial Proteostasis Lab (Kaye Truscott) / 25
Molecular Self-Assembly and Nanoarchitecture Group (Adam Mechler) / 26
Multifunctional and Advanced Interfaces Group (Wren Greene) / 27
Muscle Biochemistry Group (Robyn Murphy) / 28
Neurodegeneration Biology and Biomarker Group (Lesley Cheng Sim) / 29
Neurodegeneration and Neurorepair Group (Jacqueline Orian) / 30
Optical Spectroscopy of Atmospheric, Astrochemical and Biological molecules (Evan Robertson) / 31
Peptide Chemical Biology Group (Wenyi Li) / 32
Protease Biology Group (Lakshmi Wijeyewickrema) / 33
Structural Biology and Bacterial Pathogenesis Group (Begoña Heras) / 34
Translational Biology Group (Hamsa Puthalakath and Michael Foley) / 35
Vascular Cell Death, Clearance and Inflammation Group (Amy Baxter) / 36
Vascular Therapeutics and Regeneration Group (Kazuhide Shaun Okuda) / 37
Viral and Structural Immunology Group (Stephanie Gras) / 38

Cancer Biology, Cell Polarity, and Tissue Architecture Group


Cell polarity, or asymmetry, a basic property of all cells, is encoded by an evolutionarily conserved genetic program that coordinates the differential division of stem cells, the positioning of cells within an organ, and the precise architecture of the organ. Disruption of this genetic program leads to tissue disorganisation and can promote the first steps of cancer. Our laboratory studies how cell asymmetry and tissue organisation can regulate cancer initiation, progression and metastasis. We aim to devise therapeutics to help tumours to "reorganise" themselves, thereby stopping the cancer's growth and spread. We also study how the cell polarity genetic program's involvement in tissue regeneration on earth and in space, as well as in developmental processes (e.g. blood cell production and function). Our multi-disciplinary approach encompasses state of the art imaging, genetically engineered mouse models, and the use of powerful genetic and chemical screens. We work closely with cancer clinicians and pathologists.

"Re-organising" early breast and prostate cancer as a preventative approach

Loss of the proper orientation of cells within a tissue, known as cell polarity, is one of the hallmarks of breast and prostate cancer and is correlated with more aggressive and invasive cancers. How loss of cell polarity occurs and how it contributes at the molecular level to tumour formation remains unknown. Using approaches including RNAi screening, we identified genes that mediate the tumour suppressive functions of cell polarity. We use this new molecular information to re-establish normal tissue architecture through clinically approved drugs and aim to stop early tumour growth.

The evolutionary origin of cancer

How did cancer begin? The advent of the first multicellular animals from single cells required new molecular mechanisms that allowed cooperation between cells and suppressed any conflicts that enhanced the individual fitness of any one cell, stopping them from "cheating" to the detriment of the organism. We study these very first cancer protective mechanisms in one of the oldest and simplest animals on earth, *Trichoplax*. Most human disease genes including cancer suppressing genes are found in this organism. By studying how it escapes cancer, we hope to gain insights into the origins of cancer that will be translated to humans.



a), *Trichoplax adherens*, one of the simplest and most ancient animals; b), Expression of cell polarity protein Scribble (Red) in 3D MDCK cell cultures; c), enucleation of a mouse red blood cell

The role of gravity in tissue organisation and regeneration

Since life began on Earth four billion years ago, gravity has been the only constant environmental factor accompanying the evolution of life. The role gravity has played with respect to the establishment and maintenance of tissue organisation in multicellular organisms is unknown. Physiological effects resulting from hypergravity or microgravity (weightlessness) have been noted with detrimental effects on bone and muscle turnover, and wound healing in humans. This is a crucial factor for international space programs which aim at a long-term stay of humans and bioregenerative life support systems in space. Through our close connection with the German Aerospace Centre (DLR), and in partnership with TiHo, Hannover, we are testing for the first time how altered gravity may affect the development of tissue architecture and regenerative programs in the simplest and most ancient animal, *Trichoplax*. We use short-term space flights in sounding rockets and ground-based microgravity simulators to provide new insights into how all animal tissues are organised and regenerated.

How did the red blood cell lose its nucleus?

Red blood cell enucleation (extrusion of the nucleus) is a feature of mammalian blood required for proper circulation of red blood cells (RBCs) through the microvasculature and increased haemoglobin concentration

in blood. A major challenge for transfusion medicine is the difficulty obtaining sufficient supplies of specific RBC subtypes. Despite advances in *in vitro* production of human RBCs from hematopoietic, embryonic, and induced pluripotent stem cells, the reduced ability of these cultured cells to fully enucleate remains a major hurdle. We study the molecular mechanisms regulating the enucleation process to provide improved strategies for the efficient and rapid production of RBCs for self-generated patient transfusion.

Lab Head: Professor Patrick Humbert (P.Humbert@latrobe.edu.au)

Lab members: Ms Bree Mellberg; Mr Lucas Newton; Ms Yuliya Stepkina

Fields of Study:

Cell development, proliferation and death; Cellular interactions; Cancer cell biology; Space Sciences; Cell Polarity; Erythropoiesis

Capabilities and Techniques:

3D cell cultures; Animal models of disease; Functional screening; CRISPR-Cas9 gene editing; Microscopy – electron, confocal, light; Flow cytometry; Protein biochemistry; Microgravity simulation; Real microgravity experimentation, sounding rockets

Translational Opportunities:

Human patient-derived 3D organoid cultures; Pre-clinical animal models of cancer for drug screening.

Cell Death and Survival Group


Our group is uniquely positioned at the cross-roads of SABE and the School of Cancer Medicine (Olivia Newton-John Cancer Research Institute). Our research investigates how our cells determine their fate. In particular, we aim to understand what goes wrong in this decision-making process in disease and to then utilize this knowledge for therapeutic intervention. Using a combinatorial approach based on biochemistry, cell biology, and animal-based techniques, we seek to decipher the molecular mechanisms regulating cell fate decisions. Our research focuses on the pathways of cell death known as apoptosis, and of cell survival known as autophagy. Deregulation of these processes have been implicated in diseases such as cancer and inflammatory bowel disease.

Targeting apoptosis for cancer treatment

Our Group has a long and productive track record in the study of the intrinsic apoptotic pathway regulated by the BCL-2 family of proteins. Deregulation of this pathway can result in insufficient cell death and is a hallmark of cancer. Over the years, we have made significant contributions to how this pathway is regulated and to international collaborations that have led to the development of clinically approved drugs targeting it. Our current program investigates the clinical application of drugs that induce apoptosis in incurable and aggressive solid cancers with low overall survival rates. As part of this program, we collaborate with pharmaceutical companies such as AstraZeneca.

Novel regulators of intestinal homeostasis

We also have a research program that focuses on the cell survival pathway of autophagy. This evolutionarily conserved process of cell recycling enables unwanted cellular material to be degraded by the lysosome and is critical for maintaining a healthy cell. Mutations in the pathway have been strongly associated with inflammatory bowel disease. We are currently investigating how well-established regulators of autophagy regulate intestinal homeostasis at a molecular level. Our studies have yielded unexpected but exciting results showing that a key autophagy regulator also has a moonlighting role in another pathway that is critical for maintaining a healthy gut.



Gastrointestinal organoids stained for critical cellular markers
Photo credit Doug Fairlie and Erinna Lee.

Identifying novel immune-oncology regulators

Many of the latest approaches to cancer treatment involve harnessing the immune system to kill rogue tumour cells. Whilst this process is well understood, all of the molecular players that dictate responsiveness have yet to be identified. We recently entered a collaboration with the Molecular Immunology Laboratory, headed by Conor Kearney at ONJCRI, to use CRISPR/Cas9-based screening approaches targeting boutique libraries of genes involved in cell death and survival, as well as membrane trafficking. We expect to uncover critical new regulators of this process that could serve as future targets in efforts to improve immune-oncology outcomes.

Drug screening

A recent successful grant application has enabled the ONJCRI to purchase a liquid handling robot. Our lab has now established an efficient experimental pipeline using this robot that allows for the screening of drug libraries on cancer cells. We now plan to initiate a new screening platform that enables researchers to collaborate with us on projects that facilitate the discovery of new strategies for targeting cancer cells.

Lab Heads:

Associate Professor Doug Fairlie (D.Fairlie@latrobe.edu.au) and Associate Professor Erinna Lee (Erinna.Lee@latrobe.edu.au)

Lab members:

Ms Umairah Binte Abdul Khalid;
Ms Julie Juliani;
Ms Tiffany Harris;
Mr Kristian Caracciolo;
Ms Nina Rogers.

Fields of Study:

Apoptosis;
Autophagy;
Cell Biology;
Cancer;
Gastrointestinal Biology and disease.

Capabilities and Techniques:


Cell survival and death assays; high throughput drug screening; genetic editing of apoptosis and autophagy pathways; genetic mouse models of disease.

Translational Opportunities:

Drug screening;
Mechanism of action studies;
Drug validation.

Cell Signalling and Rare Metabolic Disease Group

Our Group investigates the complex interplay between cells and their environment to better understand processes that underpin animal development and health. Our work takes us from the molecular scale, understanding how proteins control cell-to-cell communication, through to body tissues and whole organism scales where we look at physiology in disease. Our animal of choice is the fruit fly *Drosophila melanogaster*, which has a fast life cycle, can be easily manipulated at the genetic level, and has many similarities with humans, from its genes to entire body system processes. We aim to use *Drosophila* as a biomedical research tool to reveal new mechanisms of cell signalling control, as well as learn how disease affects the body for targeted therapy development. The research is highly collaborative and involves local, national and international partners.



We use *Drosophila melanogaster* to model rare human inherited metabolic diseases. (Image credit: Sarah Mele)

Models of rare inherited disorders

There are more than 1,000 inherited metabolic disorders (IMDs) known which collectively affect approximately 1 in 800 births. Tragically, IMD often cause rapid neurological decline and death during infancy, and due to their rarity and large overall number, IMD remain a major challenge for treatment development. Our Group is addressing this by generating fly models of IMDs for the purpose of understanding these diseases and finding new treatments. IMDs are unique amongst inherited disorders because they are often very responsive to dietary changes. As *Drosophila* has a fully customizable diet available, we are performing large-scale nutrient screens on our fly IMD models to identify dietary compositions that restore health parameters. The goal of this work is to translate our findings to mammalian models and into the clinic to reduce the suffering of those with IMDs.

Understanding blood cell biology

Our work on cell signalling control has led us to study the macrophage: a highly versatile blood cell responsible for a plethora of activities that support organismal health. Despite having been studied for more than a century, we still know very little about how their numbers and distribution around the body are controlled. In *Drosophila* more than 95% of the blood cells are macrophages, making them ideal for such studies.

We have developed a suite of sophisticated genetic and imaging tools for their study. We currently have a number of projects focused on macrophage biology including: identifying cell signalling pathways that control macrophage number, and applying new approaches to study their response to environmental and genetic perturbations.

Mechanisms of cell signalling

A major focus of our research concerns cell signalling at the earliest stages of animal development - in the embryo. Here we study a receptor pathway that is activated in a unique spatial manner for a critical developmental process, the control mechanism of which is poorly understood. We are applying biochemical and structural biology approaches in concert with in vivo developmental biology techniques to reveal how signalling is controlled at the molecular level. Interestingly, a key player in this mechanism is related to bacterial toxins and vertebrate immunity effectors usually associated with cell killing. Unravelling how such a molecule functions in the early embryo to control receptor activity may therefore shed light on several areas of biology, as well as

have implications in the development of therapeutics for developmental disorders and cancer.

Lab Head: Dr Travis Johnson
(T.Johnson@latrobe.edu.au)

Lab members:
Dr Sarah Mele;
Dr Jemma Gasperoni;
Ms Grace Jefferies;
Ms Emily Kerton;
Ms April Lewis;
Ms Sabah Jbara;
Ms Zoriana Novosiadla.


Fields of Study:
Genetics; Molecular Biology; Cell Biology;
Developmental Biology; Disease models.

Capabilities and Techniques:
Confocal microscopy; Gene-editing;
Transgenesis; Genetic analysis;
Nutrigenomics.

Translational Opportunities:
Rare inherited disease therapeutics;
Precision diet screening; imaging devices.

Computational Chemistry Group

Our group does chemistry by computer to better understand the structures and properties of molecules and how they react. Our research is highly interdisciplinary and lies at the interface of materials, biology, physics, and chemistry. The goal of our research is to develop quantum chemical tools to calculate accurate chemical properties and then apply these tools to problems of chemical structure, mechanism, and design. We employ a range of computational techniques including empirical force fields, density functional theory, and ab initio quantum chemical methods. Our applied studies range from optical materials design to medicinal drug design, including the computational design of optical materials for use as LEDs, new materials for hydrogen storage, efficient catalysts, and accurate modelling of biological molecules. The research is collaborative and involves local, national, and international partners.



Various molecular chemistry structures

Designing new chemistry

Chemistry is in an age where our ability to rationally design and tailor new molecular systems has led to remarkable developments in materials science, drug design, catalysis, and green chemistry. The capacity to engineer new molecules for specific roles is in large part underpinned by advancements in computational chemistry, which is now able to reliably predict the structures and function of molecular systems. Our group has a strong track record in predicting new chemistry and designing molecules for specific use as chemical reagents, medicines, and materials. In collaboration with Professor Jason Dutton and Professor Robert Gilliard, we are demonstrating the remarkable benefits that arise from the synergy of computational chemistry together with advanced synthetic chemistry that provides the capacity for molecular engineering.

Understanding Chemical Reactivity

Optimization of chemical processes is enhanced by an understanding of the mechanism of reaction; it is difficult to optimize an industrial process if the mechanism is not known, if the reacting species in the flask are ill-defined, or do not even exist. Our group has significant expertise and experience in probing

chemically important reactions. Current projects include the mechanism of reaction of halogenation reactions with iodine reagents. Techniques to introduce halogen atoms into organic molecules are of fundamental importance to industry because of the ubiquity of these atoms in useful molecules such as medicines, agricultural chemicals, materials, and specialty chemicals.

Light-emitting materials

Our group is focused on the design and understanding of optical properties of molecular systems, including boron-doped organic molecules and metal-based (ruthenium, iridium) complexes. These are projects are often carried out in collaboration with experimental scientists. One current focus is the incorporation of boron into polycyclic aromatic hydrocarbons (PAH), which has become a key strategy in the search for new molecular materials such as LEDs. Our research seeks to harness the potential of boron, which is increasingly occupying a prominent position in both molecular optoelectronic materials and medicinal drug discovery due to its 'magic' qualities of its ability to form a variety of bonds and capacity to mimic metal properties.

Molecular Shape

Our research is driven by a curiosity of molecular structure and chemical bonding. Molecular science is underpinned by a fundamental relationship between structure and function; understanding the function of molecules as medicines, industrial chemicals, and useful materials, requires a fundamental understanding of molecular structure and shape. We apply the full array of computational chemistry tools to probe the shape and structure of molecules of importance to biochemistry, astrochemistry, optoelectronics and sensing, and materials chemistry.

Lab Head: Associate Professor David Wilson
(David.Wilson@latrobe.edu.au)

Lab members: Mr Andrew Molino;
Ms Aishvaryadeep Kaur; Mr Johnny Agugiario; Ms Ishara Peiris; Mr Matt Gosch.

Fields of Study:
Theoretical and Computational Chemistry.

Capabilities and Techniques:
Computational chemistry; molecular structure analysis; reaction mechanism.

Translational Opportunities:
Reaction design and optimisation; optoelectronic materials design.

Dead Cell Clearance and Infection Group


Apoptosis, a type of a programmed cell death, is a key host defence that destroys pathogenic niches in infected cells, kills infectious agents and initiates adaptive immunity. Dying cells have an active role in alerting the immune system, by attracting phagocytes (e.g., dendritic cells, macrophages). Furthermore, dying cells often break into 'bite-sized' membrane-bound fragments called 'apoptotic bodies' (ApoBDs) to enhance corpse engulfment and removal by phagocytes (a process known as 'efferocytosis'). In turn, the phagocytes process the ApoBD contents and activate their own signalling programs, specific to the type of molecular messages that they have recognised. Our group aims to advance current understanding of the dynamic host-pathogen interaction along apoptosis–efferocytosis axis and to develop novel therapeutics for respiratory infections, the leading pathogenic causes of global morbidity and mortality.

Efferocytosis-mediated viral entry and inflammation

Severe SARS-CoV-2 infection is typified by an exacerbated pro-inflammatory 'cytokine storm', which develops after peak viral titre. Macrophages, rapid cytokine producers upon pathogen infection, are a major driver of COVID-19-associated hyperinflammation. Hitherto, it remains unclear how SARS-CoV-2 gains entry into macrophages, which lack canonical receptor required for viral entry, and triggers hyperinflammation. We recently discovered that SARS-CoV2-induced ApoBDs mediate a novel viral uptake pathway, by primary human macrophages and other phagocytes. Of great clinical significance, SARS-CoV-2-ApoBD-engulfing macrophages, secreted markedly high levels of cytokines. We thus aim to uncover the novel mechanism of infection-derived ApoBDs in facilitating viral uptake and driving inflammation, and develop novel ApoBD-targeting therapeutics to tackle other apoptosis-inducing newly emerging virals. threats.

Anti-mycobacterial immunotherapy

Mtb and many intracellular bacteria have evolved to prevent host apoptosis to escape host immunity and enhance their growth in



ApoBD formation in an apoptotic Jurkat T cell, captured by lattice light-sheet microscopy.

infected cells. Hence, therapeutic induction of infected cell apoptosis and promotion of ApoBD formation may reinstate host anti-infective responses through ApoBD-mediated T cell activation. We will conduct world-first groundwork for the therapeutic enhancement of ApoBD formation to promote host-mediated clearance of Mtb infection by combining MAIT cells (for specific apoptosis induction of infected cells) and pharmacologically inhibiting ApoBD formation.

Novel regulators of ApoBD formation and efferocytosis

Apoptotic cell death underpins many critical physiological and pathological processes, not only infection but also cellular homeostasis, development, ageing and immunity. The communication between dying cells and healthy cells can be relayed by ApoBDs. In addition, the fragmentation of apoptotic cells into "bite-sized" ApoBDs mediate the rapid and efficient debris removal via efferocytosis. However, the molecular basis of ApoBD formation and efferocytosis remains poorly understood. We seek to identify novel regulators of ApoBD formation using proteomics and CRISPR/Cas9 screening.

Drug screening and development

As ApoBD formation and efferocytosis play important roles in many critical cellular processes and diseases, we aim to perform multiple drug library screening as well as rationalised drug designs to identify ApoBD-targeting small molecules as novel therapeutics.

LabHead: Dr Kha Phan
(Thanh.Phan@latrobe.edu.au)

Lab members:
Ms Bo Shi; Ms Dilara Ozkocak;
Mr Omar Audi.

Fields of Study:
Cell Biology; Microbiology; Innate Immunology.

Capabilities and Techniques:
Advanced imaging; Multicolour flow cytometry and sorting; PC3 pathogen handling; CRISPR/Cas9 gene editing.

Translational Opportunities:
Drug development; Disease diagnostics.

Dying Cell Clearance and Disassembly Group


Billions of cells die daily as part of normal turnover in various organs. It is vital that dying cells are rapidly removed as their accumulation has been linked to inflammation, autoimmunity, cancer and infection. To aid efficient removal of dead cells, dying cells often disassemble into smaller fragments for neighbouring cells to engulf. Certain cellular components can be packaged selectively into these fragments to regulate tissue repair and immunity. We aim to understand the machinery that controls how dying cells can disassemble into smaller pieces, the importance of cell disassembly in disease settings (e.g. influenza A infection and atherosclerosis), and identify new drugs to control this process.

Mechanism of dying (apoptotic) cell disassembly

Apoptosis (programmed cell death) occurs in all tissues as part of development, homeostasis, and pathogenic processes including infection and cardiovascular disorders. Apoptotic cells often disassemble into smaller membrane-bound extracellular vesicles called apoptotic bodies. We have demonstrated that the formation of apoptotic bodies is a highly regulated process in T lymphocytes and monocytes. We discovered a new type of membrane protrusion (coined "apoptopodia") that facilitates the separation of membrane blebs during apoptosis to generate individual apoptotic bodies. The molecular machinery that controls the formation of apoptopodia is undefined. We aim to determine the molecular machineries required for the formation of apoptopodia.

Function of apoptotic cell disassembly in pathophysiological settings

Extracellular vesicles including apoptotic bodies have been implicated to regulate physiological and pathological processes via the molecules they carry inside or exposed on their surface. The importance of generating apoptotic bodies during apoptosis in pathophysiological settings is poorly understood. We study the role of apoptotic cell disassembly in the context of viral infection. During viral infection, infected cells often undergo apoptosis to shutdown cellular machinery as a defence mechanism



Dying cancer cell undergoing disassembly. (Photo credit: Stephanie Rutter)

to limit viral replication. Phagocytic removal of infected apoptotic cells/fragments may also facilitate the spread of infection, and the phagocyte could become infected following the engulfment of apoptotic cells/fragments containing viral particles. Viral proteins have been suggested to accumulate in apoptotic bodies during apoptosis, but the role of apoptotic cell disassembly in the context of viral infection is underexplored. We study apoptotic body formation in influenza A and SARS-CoV-2 infection.

Discovery of novel drugs to modulate the apoptotic cell disassembly process

Apoptotic body formation is a key cellular process for efficient removal of apoptotic debris and intercellular communication in certain disease settings. There is a lack of drugs to target this process so identifying drugs that could modulate apoptotic cell disassembly is important. Using a novel flow cytometry-based drug screen approach, we have identified a number of drugs that can inhibit or enhance the formation of apoptotic bodies without having an impact on the level of apoptosis. Some of these drugs are FDA approved and are currently being used clinically. We aim to characterise these novel inhibitors and enhancers of

apoptotic cell disassembly in detail, in particular how these compounds could modulate the morphological steps of apoptotic body formation as well as the activities of known molecular regulators of apoptotic cell disassembly (e.g. ROCK1 kinase and pannexin 1 channel). Furthermore, whether these drugs can be used to control the apoptotic cell disassembly process in disease settings will also be examined.

Lab Head: Professor Ivan Poon
(I.Poon@latrobe.edu.au)

Lab members:

Dr Amy Baxter; Dr Donia Abied; Ms Caitlin Vella; Ms Gemma Ryan; Ms Amy Hodge; Ms Bo Shi; Ms Jascinta Santavanond; Ms Dilara Ozkocak; Ms Stephanie Rutter; Mr Omar Audi.

Fields of Study:

Cell Biology; Cell Death; Cell Clearance; Extracellular Vesicles.

Capabilities and Techniques:

Time-lapse microscopy; flow cytometry; cell death analysis; drug screening.

Translational Opportunities:

Treatment and diagnostics for infection, cardiovascular and autoimmune diseases.

Electrochemical Sensing Group

Our group conducts a range of both fundamental and applied multidisciplinary research focused on expanding the bounds of Analytical Science. We pursue the development of new chemistries and new technologies which will result in exquisitely low detection limits and enhanced selectivity. Building on breakthrough fundamental science, we seek to develop novel sensing technologies and miniaturised instruments for use outside the laboratory setting. For example, we hold several patents in the use of personal electronic devices such as mobile phones for sensing applications from environmental analysis to medical diagnostics. We also have on-going collaborations with a range of industries and government bodies around sensor development. Working at the interface of electrochemistry and photochemistry, we have pioneered several new approaches to detection science. Our group is a world leader in the application of electrochemiluminescence (ECL) detection to mobile phone readable paper microfluidic sensors and the development of potential resolved multi-coloured ECL or 3D ECL.

Photophysics and electrochemistry of highly luminescent transition metal complexes

We are interested in developing and investigating materials which are electroactive, materials which are luminescent and in particular, materials which exhibit both of these properties simultaneously. One area in which we are very active, is in the applications of highly luminescent Iridium, platinum and ruthenium complexes. We explore the use of such molecules (with Dr Peter Barnard and others) for applications in ultra-sensitive medical diagnostic and health testing applications.

Ultra-sensitive Electrochemiluminescence (ECL) sensing

Electrochemiluminescence, (ECL) facilitates extremely low (sub-femtomolar) detection limits for bioanalytical measurement, often outstripping fluorescence by several orders of magnitude; but current ECL detection technology consists of large laboratory instruments. We are developing new minimally invasive diagnostic technologies

based on electrochemiluminescence (ECL) detection chemistry. This will provide superior detection limits ultimately enabling the detection of biomarkers in saliva.

Android Voltammetry: A simple but powerful smartphone-based biosensing platform

The development of simple, inexpensive (yet quantitative and sensitive) sensors for environmental, medical and other sensing applications is an extremely important emerging area because it has the potential to make chemical and biochemical analysis, usually confined to the lab, more widely available. Such technology can be transformational, particularly in remote areas and in the developing world, where levels of health expenditure are low. Our patented sensing technology called Android voltammetry, developed in the Hogan lab eliminates the requirement for an instrument and harnesses the existing audio capabilities of mobile phones to facilitate electrochemical detection. Our first application for this platform (the "ElecTrobe") is set to save millions of dollars for the Australian wine industry each year. By using the audio jack to provide electrochemical stimulation we have replicated what is usually done using expensive laboratory instruments to perform "instrument free" analysis. As the data and associated metadata can be readily shared, this opens up a range of exciting possibilities for e-Health, telemedicine and "crowd sourced sensing". See <http://youtu.be/X6zSgFEhFd4> and <https://youtu.be/XUXvdd5nMcM>. We are currently developing a range of exciting new applications for this platform in the fields of environmental analysis and medical diagnostics.

Design and printing of disposable sensors for electrochemical and ECL detection

Our laboratory hosts a Diamatix materials inkjet printer, a state-of-the-art technology for the production of bespoke printed sensors in significant quantities.



Mobile phone based wine analysis using Fourier Transform AC voltammetry

The materials printer affords unprecedented scope for printing novel sensor designs. We use it to explore the influence of novel sensor geometries on sensitivity in electrochemical and ECL sensing.

Lab Head: Professor Conor Hogan (C.Hogan@latrobe.edu.au)

Lab members: Dr Mohammad Reza Moghaddam; Dr Robert Sikos; Ms Laena D'Alton; Ms Samridhi Bajaj; Ms Helmini D G Dona; Mr David Macedo.

Fields of Study:

Chemistry; Analytical Chemistry; Electrochemistry; Luminescence, Biosensors.

Capabilities and Techniques:

Unique combination of expertise in electrochemistry, photophysics and sensor technology; Proven ability to translate / commercialise basic science for real-world sensor technology applications.

Translational Opportunities:

Proven ability to translate / commercialise basic science for real-world chemical and biosensor technology applications. Follow us on Twitter @hogansheroeslab and Facebook.

Exosomes, secretome and systems biology


Our major research interests are in exploring the role of extracellular matrix components (soluble secreted proteins and extracellular vesicles) in cancer and intercellular communication. Our lab integrates proteomic, genomic and bioinformatics methodologies to study cancer progression. In addition to medical research, we are also interested in basic science projects including the biogenesis of exosomes and the role of exosomes in intercellular communication.

Exosomes in the tumor microenvironment

Exosomes are 40-100 nm diameter membrane enclosed extracellular vesicles released by various cell types, including cancer cells. For tumors to progress, bidirectional crosstalk between different cells occurs within the tumor and its surrounding supporting tissue. A tumor can be considered as a complex tissue or organ with abnormal cells harboring genetic mutations, typically referred to as tumor or cancer cells, enmeshed within the surrounding and interwoven stroma, the epithelial parenchyma, which provides the connective tissue of the tumor. Stromal elements include the extracellular matrix as well as other cell types that are activated and/or recruited to the tumor microenvironment such as fibroblasts, immune and inflammatory cells, fat cells and endothelial cells of the blood and lymphatic circulation. Recent literature indicated that all aspects of cellular tumorigenicity are profoundly influenced by reciprocal interactions between responding normal cells, their mediators, structural components of the extracellular matrix, and genetically altered neoplastic cells. Exosomes have recently been recognized as important mediators of the cross-talk in the tumor microenvironment. Exosomes derived from tumor cells have been shown to have both pro- and anti-tumorigenic properties. Our lab is interested in studying the role of exosomes in the tumor microenvironment.

Proteogenomics analysis of exosomes and extracellular vesicles

Recent studies have highlighted the secretion of oncoproteins including mutant proteins via exosomes. However, a prior knowledge of the mutant protein is a prerequisite in all of the published studies.



Exosomes role in tumor microenvironment. (Picture credit: Gangoda et al. 2015, Proteomics)

A global approach to systematically identify mutant proteins secreted through exosomes will aid in elucidating the functional roles of exosomes. In order to identify the mutant proteins that are secreted by a cell via exosomes, we use global proteogenomics approach. In addition to functional implications, as exosomes may contain disease causing proteins including mutant proteins/RNA, assaying for mutant or disease-causing proteins/RNA as disease biomarkers may provide the required specificity for a biomarker test.

Systems biology - exosomes and colorectal cancer

Constant dynamic interactions between a cell and its surrounding tissue microenvironment are important in maintaining the differentiated state of a cell. While such organised intercellular signalling cascades are pivotal in cellular proliferation, sustained disruption of key signalling events render the cells susceptible to malignancy. Our group uses systems biology or bioinformatics approaches to study the molecular mechanisms of colorectal cancer. We use proteomic and genomic technologies to study colorectal cancer cells and integrate bioinformatics methods to make biological sense of the obtained data. With the explosion of datasets from high-

throughput techniques, systems biology approaches hold immense promise to investigate such data and present them at the context of the disease. It has to be noted that high-throughput data should be dealt carefully owing to the noise and systemic pitfalls. Our group develops computational tools to analyze such datasets and integrate them with heterogeneous datasets obtained from similar biological experiments using statistics and computation.

Lab Head: Professor Suresh Mathivanan (S.Mathivanan@latrobe.edu.au)

Lab members: Dr Pamali Fonseka; Dr Christina Nedeva; Dr Sarah Stewart; Mr Sai Chitti; Mr Sanjay Shahi; Mr Taeyoung Kang; Mr Rahul Sanwani; Ms Akbar Marzan; Mr Kyle Bramich.

Fields of Study:

Exosomes; Cancer; Extracellular Vesicles; Proteomics; Bioinformatics

Capabilities and Techniques: Extracellular vesicles isolation and characterization; Mass spectrometry; IVIS imaging; Confocal microscopy.

Translational Opportunities:

Treatment for cancer; Therapies to block metastasis; Treatment for cancer cachexia; Cancer prevention.

Fluorescence Chemical Biology Group


Our group develops novel fluorescent probes for understanding and manipulating fundamental biological processes regulating cell fitness and their association with aging and diseases. Our goal is to generate molecular tools that can report on changes such as protein folding, modification and degradation in a native environment such as in live cells and organisms to reveal hidden molecular level mechanisms for the understanding, diagnosis, and potentially treatment of diseases in particular neurodegenerative diseases. The group's work combines multidisciplinary approaches, ranging from synthetic and analytical chemistry, bioconjugation chemistry, molecular and cell biology to bioinformatics, and involves collaborations with local, national, and international partners working on Parkinson's, Huntington's, Motor Neuron Diseases (MND), leukemia and rare diseases.

Protein Damage in Neurodegeneration

Neurons are postmitotic long-lived cells. Over time, with the accumulated exposure to stress (from ROS production, DNA damage, infection, etc.), the protein quality control system becomes less efficient, leading to accumulation of protein damage and eventually neuron death. Our Group has developed unique chemical tools that can tag on damaged proteins, including those cannot fold properly (e.g. unfolded, misfolded, or aggregated) or undergo aberrant modifications. These tools can selectively tag on damaged proteins, turn on their fluorescence, allowing us to quantify the level of damaged proteins as a measure of proteostasis capacity, imaging unfolded and aggregated protein in cells, mapping subcellular polarity changes in response to protein unfolding, as well as identify those proteins to study protein stability in cells. These tools have been used in the study of Huntington's, Parkinson's, MND, virus infection and antimalaria drugs.

Tracking and Measuring Autophagy

Autophagy ("self-eating") is a cellular housekeeping process in which unwanted components are identified, degraded, and recycled, greatly contributing to cell homeostasis and development, but also the prevention of various diseases. Autophagy is a



multi-step, dynamic process. Dysregulation of autophagy has been linked to many diseases, such as neurodegeneration, cancers, cardiovascular and infectious diseases, with different steps of the pathway being impaired. Current tools to study autophagy rely on antibodies or fluorescent protein-based sensors, both of which require modification of the cells prior to the study. Our group develop fluorescent chemical probes that are highly specific to autophagy, which allow us to follow the dynamic process of autophagy and quantify its activity in situ and in a high throughput manner without the prerequisite of genetically modifying the cells. We use these probes in a range of cell models including those derived from Parkinson's patients and model organisms like zebrafish and demonstrate their applications for drug screening, understanding disease mechanisms, as well as studying fundamental biological processes.

Using Luminescence to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is a growing health issue recognised by the World Health Organisation (WHO), which has listed AMR as one of the top 10 global public health threats. For example, as a consequence of antibiotic misuse in dental

practice, AMR in oral pathogens is becoming more and more prevalent. We develop novel fluorescence for visualizing and inhibiting bacteria growth including those resistant to conventional antibiotics. Some of these molecules also present photodynamic therapy activities, which provide the possibility of using light to kill bacteria in a selective area in a controllable way.

Lab Head: Associate Professor Yuning Hong (Y.Hong@latrobe.edu.au)

Lab members: Dr Bicheng Yao; Dr Siyang Ding; Dr Xavier Zhang; Mr Timothy Gialeris; Ms Soheila Sabouri; Mr Tze Cin Owyong; Ms Karren Jiamin Zhao; Mr Liang Tan; Mr Jack Spencer.

Fields of Study:

Analytical Biochemistry; Bioassays; Biologically Active Molecules

Capabilities and Techniques:

We specialize in fluorescent probe design and synthesis and have developed novel fluorescence probes for protein oligomers, for unfolded protein response, for targeting and imaging organelles, for enzyme activity, for autophagy activity, etc.

Translational Opportunities:

Material transfer; Early detection of neurodegenerative diseases; Disease treatment evaluation; Assay kits/device development based on our materials.

Immunometabolism and Macrophage Biology Group

Every cell in our body requires energy to perform their specific functions. Generally, this is a well-controlled and ordered process. However, in some settings, the ways in which cells obtain this energy is altered and has important functional consequences.


We are now learning that the metabolism of immune cells is intricately linked to their function, where distinct metabolic configurations are ascribed to different phenotypes.

Our research aims to understand the link between what immune cells 'eat' in our tissues and how this is connected to their normal biology, response to infections, and inflammatory diseases such as high blood pressure and diabetes.

Macrophages go 3D

The cell type we focus on are macrophages, innate immune cells that acquire specialised pro- or anti-inflammatory functions upon responding to stimulatory cues (e.g. toll-like receptor agonists and cytokines) in their local tissue environment. Macrophages therefore have a variety of responsibilities including protecting us from invading pathogens (bacteria, viruses, and parasites), promoting inflammation and tissue repair. Macrophages are also unique in that they are the only immune cells derived from two developmental origins: from progenitors, which seed all tissues during embryonic development, and on command from haematopoietic stem cells, which give rise to circulating precursors that infiltrate tissues throughout adulthood (Wright & Binger. Pflugers Arch 2017).

As the tissue environment is a major controller of macrophage function, understanding their function with classical 2D in vitro culture systems is impossible. The aim of this project is to develop 3D systems that better recapitulate the tissue microenvironment and support TRM function. We are interested in developing in vitro models that better mimic tissue environments. Using 3D printing, macrophages are suspended into different environments and the effect of this on their function is measured. We are particularly



Confocal microscopy image of murine macrophages. (Photo credit: Katrina Binger)

interested in modeling tissues like the lung microenvironment to better understand how macrophage function occurs in this specialised environment during infection with respiratory viruses such as Sars-CoV-2, influenza and others.

Mechanosensing metabolism

Our recent data shows that the interaction of macrophages with the extracellular matrix (ECM) is important for their function (McGowan et al iScience 2022). We think that this 'mechanosensing' is a critical, but underappreciated modulator of macrophage biology. In this project students will employ proteomics to identify proteins that regulate macrophage interaction with the ECM, and investigate their role in metabolism.

Dietary salt

It has recently emerged that small molecules, such as metabolites and electrolytes, have significant effects on macrophage phenotypes via 'reprogramming' their cellular metabolism; involving the activation of signalling pathways, expression of metabolic enzymes and proteins, increased uptake and storage of nutrients, and physical remodelling of mitochondria. We previously reported

that high dietary salt increased sodium (Na⁺) in tissues that subsequently modulated macrophage phenotypes: increasing pro-inflammatory responses and glycolytic metabolism, while inhibiting protective anti-inflammatory functions and mitochondrial respiration (Binger et al., J Clin Invest 2015; Jantsch et al., Cell Metab 2015). The aim of this project is to understand how sodium reprograms macrophage metabolism.

Lab Head: Dr Katrina Binger
(K.Binger@latrobe.edu.au)

Lab members:

Mr Sean Cutter; Ms Kaitlyn Ritchie;
Ms Emily Field; Ms Jennessa Ng.

Fields of Study:

Cardiovascular disease; Immunology;
Inflammation; Fibrosis; Cell Biology;
Metabolism; Biochemistry; Molecular
Biology.

Capabilities and Techniques:

3D primary cell culture; gene and protein
expression assays; animal models of
disease; microscopy; metabolism
analyses.

Translational Opportunities:

Biomedical therapies for fibrotic control
and inflammatory diseases.

Inflammation and tumour progression group


Our research aims to understand the structure and function of key molecules in innate immunity and tumour progression and to harness this information for the development of novel therapeutics to treat infectious disease, inflammatory disease and cancer. In particular, we aim to precisely define and translate the unique molecular mechanisms of innate defense peptides and the heparan sulphate (HS)-degrading enzyme heparanase in immunity and tumour progression. Towards this aim, our interests are focused on two main research themes, to define (i) the role of heparanase and investigate its drug targeting in the disease settings of cancer and inflammatory disease, including the important cardiovascular disease atherosclerosis, and (ii) the molecular basis of membrane-targeting by defensins, its importance in innate defense, and to use this information to develop novel antimicrobial and anticancer molecules.

Heparanase function and drug targeting in inflammatory disease

Cell migration is critical in the initiation of inflammation and to combat infection. The HS-degrading enzyme heparanase plays a key role in these processes by facilitating the migration of immune cells. As such, heparanase can also promote chronic inflammation that underpins various inflammatory diseases and therefore is an attractive anti-inflammatory drug target. Atherosclerosis is a chronic inflammatory process that is a major contributor to myocardial infarction and stroke – key sources of morbidity and mortality. We have defined heparanase as an important driver of atherosclerosis and are now assessing heparanase inhibitors as novel anti-atherogenic drugs to prevent and treat these cardiovascular diseases.

Heparanase function and drug targeting in tumour progression

The ability of malignant tumour cells to escape from primary tumour sites and spread through the circulation to other sites in the body is what makes cancer such a deadly disease. Essential in these processes of tumour growth and spread, are metastasis - where tumour cells move into and out of tissues and the vasculature, and angiogenesis – where new blood or



Cytoskeletal proteins in human cancer cells (Photo credit: Guneet Bindra)

lymphatic vessels are formed in and around a solid tumour. Heparanase has been linked to promoting tumour metastasis and angiogenesis and therefore represents an attractive anti-cancer target. Our lab has generated unique heparanase knockout mice that we are using to define the precise role and contribution of heparanase to tumour progression in the settings of breast, colon and prostate cancer, towards determining the appropriate application of heparanase inhibitors for treatment.

Antimicrobial and Anticancer Defensins

Antimicrobial peptides such as defensins are natural innate immunity molecules found throughout the plant and animal kingdoms and are attracting clinical interest for their unique antimicrobial properties against bacterial, fungal and viral pathogens, as well as their ability to target and kill cancer cells. We defined a key mechanism of action of defensins involving the specific recognition of membrane phospholipids that results in permeabilisation and death of target and anticancer therapeutics. cells. We focus on defining the precise molecular basis of the specific membrane-targeting activity of defensins to develop new potent antimicrobial and anticancer therapeutics.

Lab Head: Professor Mark Hulett
(M.Hulett@latrobe.edu.au)

Lab members: Dr Fung Lay; Ms Gemma Ryan; Dr Tien Nguyen; Mr Matt Hein; Ms Zoe Day; Ms Serenay Demir; Mr Nick Bronchinetti; Mr Gavan Frances, Ms Chloe Bourchier.

Fields of Study:

Biochemistry; Cell biology; Innate immunity; Inflammation; Cancer biology; Cardiovascular disease.

Capabilities and Techniques:

Molecular biology; gene expression analysis; protein expression, purification & quality control; protein-protein & protein-lipid interaction; mammalian cell culture; live cell electron microscopy; cell viability & drug testing; flow cytometry; mechanistic cell death assays; immunohistochemistry; heparanase activity; inflammation/cytokine profiling; in vivo mouse models of tumour progression, inflammatory disease; heparanase conditional gene knockout mouse models.

Translational Opportunities:

In vitro mechanistic & in vivo functional studies for infection, inflammatory disease & tumour progression; peptide & small drug therapeutics development & preclinical testing. Track record of translating research discoveries in partnership with biotech companies e.g. Progen Industries, Hexima Ltd, Wintermute Biomedical.

Inventing Chemistry Group

Our Group seeks to invent new chemistry with a broad philosophy of achieving this by making molecules as uncomfortable as possible. Electrons dominate the properties of molecules and in projects spanning the periodic table we consider molecules that either have too many or too few electrons. These new molecules are typically highly reactive and often result in the discovery of completely new reactions. We use a combined effort to interrogate molecules and reactions involving synthesis, spectroscopy, structural characterization and finally theoretical studies. In the latter area we undertake both predictive theoretical studies, especially in the area of chemical compounds that are too toxic or reactive to handle, and also to rationalize observations that are made by our group and others. Overall the goal of the group is to increase understanding in what is possible in chemical synthesis.

Discovering Organic Chemistry with an Inorganic Touch

Carbon has a privileged place in chemistry, and the entire field of organic chemistry is built around it. We however don't view carbon as distinct from any other chemical element and treat it as just another metal. Using this philosophy we have discovered a number of molecule classes and reactions that are very simple, but were completely unexplored simply because a classically trained organic chemist wouldn't think that way. For example in metal chemistry one can generate a molecule by taking away electrons from the metal and replacing them with ligands, or conversely adding electrons and removing ligands. It turns out carbon can behave exactly the same way, which in turn gives carbon based species that are extremely reactive in classic organic chemical transformations.


Super Charged Halogenation Reagents

Halogenation, the addition of fluorine, chlorine, bromine or iodine to simple organic feedstocks are some of the most important transformations in chemistry, occurring on a multi-million ton scale. Elemental halogens (e.g. Cl_2) are efficient at this, but are ferociously difficult to handle on a small scale. We are developing improved halogenation reagents based on I-X ($\text{X} = \text{F},$

Cl, Br) bonds in extremely electron poor environments that are more reactive than elemental halogens, but offer a vastly improved safety and handling profile. We have also found that organic chemists are frequently wrong in invoking how iodine reagents work and are carrying out a campaign to correct the literature.

Gold Chemistry for Organofluorine Synthesis

Fluorine holds a special place in medicinal chemistry, with half of top selling drugs containing a C-F bond. However, it is difficult to controllably change C-H into C-F. We have discovered that Au-F compounds are effective for performing this transformation. In this project we are using simple and cheap fluoride sources, combined with electrochemistry to generate extremely electron poor and thus reactive Au-F molecules that can catalytically effect the transformation of C-H into C-F bonds without degrading other parts of the druggable molecule of interest. In perusing this goal we have also uncovered a raft of other interesting reactivity surrounding the Au-F bond, which is generally unexplored due to its unstable nature.



Structural characterization and spectroscopy of a small molecule

Predictive Theoretical Chemistry

Sometimes one has good ideas that for a reason or another can't be actioned. In concert with the Wilson group we have an ongoing program in predictive theoretical chemistry. One of the main focusses is Beryllium chemistry. Beryllium has a very rich reactivity but is hardly explored due to its extreme toxicity. We predict what might be possible in the computer, and international groups with the appropriate skills test our predictions in their labs.

Lab Head: Professor Jason Dutton
(J.Dutton@latrobe.edu.au)

Lab members: Mr Lachlan Sharp-Bucknall; Ms Tania; Mr Lachlan Barwise; Ms Biljana Vujci; Ms Aseel Bakro; Mr Jason Benetts; Mr Benjamin Davis; Mr Luke Vincent-Blood.

Fields of Study:

Inorganic chemistry; Organic Chemistry; Theoretical Chemistry.

Capabilities and Techniques:

Complex chemical synthesis; Characterization of small molecules by spectroscopy; X-ray crystallography; theoretical calculations.

Translational Opportunities:

Chemical analysis; Prediction of chemical properties; Reaction planning and synthesis.

La Sense Group

Our research group is highly interdisciplinary and strongly focuses on translational research. We build new smart materials and interfaces for application in point-of-use sensors and biosensors to detect molecules of biological, medical, and environmental interest. Some of our activities involve the design, engineering, and characterization of new electrochemical sensor materials. A major goal is to develop biosensors that can detect multiple biomolecules simultaneously directly on-the-spot, where the measurement needs to be done, without sample pretreatment. Currently, a variety of projects are underway that focus on the development of biomolecular sensors for disease diagnostics. We also work closely with key industry partners in the biosensors and diagnostic fields, creating hence a pathway to the translation of new technologies.

Point-of-care biosensors for cancer diagnostics and monitoring

Blood-based cancer biomarkers represent a range of promising diagnostic analytes for the early detection and surveillance of cancer. Current detection approaches involving serology protein-based assays and circulating tumour DNA tests rely upon an intravenous blood draw, sample processing, and testing requiring a specialized laboratory setting. This project aims to advance the development of next-generation cancer biomarker detection for on-spot detection of cancer analytes using rapid and inexpensive portable electrochemical biosensors. This is expected to provide significant benefits for cancer patients, especially in remote locations, where surveillance methods can be limited and expensive for early detection of cancer and monitoring of disease recurrence during treatment.

Chemical contaminated water: biosensors for rapid, on-the-spot detection

This project aims to develop a versatile biosensor system for rapid on-site detection and monitoring of toxic per- and poly-fluoroalkyl substances (PFAS) in contaminated waterways. PFAS are also known as the 'forever chemicals' and have become a major environmental pollutant that threatens human and ecological health; in Australia PFAS contamination is prevalent

in both urban and rural areas, and all Australians are expected to have detectable levels of toxic PFAS in their blood. Current conventional PFAS detection methods rely on sample collection and transport to a centralized laboratory, which is expensive and time-consuming. Thus, there is a need for low-cost portable sensors for the on-spot monitoring of PFAS. In order to achieve specific molecular recognition for PFAS detection, this project will employ protein-based surface chemistries, where fatty-acid binding proteins will be used as the PFAS recognition elements. The produced electrode surfaces will be fully characterized and analytically challenged in 'real-world' contaminated water samples.

Multiplexed sensors

The ability to simultaneously and precisely detect multiple target analytes in biological samples is a high-reward goal of analytical sensors. Multiplexing capability is necessary for improving diagnostic effectiveness, improving the diagnostic precision for given diseases, and lowering associated costs with diagnoses and disease management. For example, in the case of cancer, most cancers present biomarkers in common with other cancers, thus detection of multiple biomarkers is required for the precise distinction of cancer types and/or location. Therefore, this project seeks to develop new electrochemical sensing platforms for the direct and simultaneous detection of multiple disease biomarkers in high-fouling biological media, for example, blood plasma or whole blood.

Detection of salivary biomarkers in cardiovascular disease

Cardiovascular diseases are the leading cause of mortality globally. In acute cardiovascular conditions, time is critical for the outcomes of disease management. Provided the ease and noninvasiveness nature of obtaining saliva, salivary biomarkers can offer a rapid and efficient diagnosis of cardiovascular diseases. This project



A point-of-use biosensor where the teststrips can be manufactured in a large scale.

will look into identifying key cardiovascular disease biomarkers present in saliva as well as developing and fully characterizing new electrochemical sensing interfaces for the detection of such biomarkers.

Lab Head: Dr Saimon Moraes Silva
(S.MoraesSilva@latrobe.edu.au)

Lab members: Currently recruiting PhD and Masters students.

Fields of Study:

Biosensors, Point-of-use diagnostics, Electrochemistry, Analytical Chemistry, Synthesis of Biomaterials and Nanomaterials.

Capabilities and Techniques:

We have expertise in electrochemistry, biomaterials, nanomaterials, and surface modification with a strong focus on interfacing materials with biological systems.

Translational Opportunities:

We work together with our industry partners to translate and commercialize the next-generation biosensors for medical and environmental applications.

Twitter: @moras_saimon

Materials design using AI and machine learning


Computation is the third arm of research, after theory and experiment. Computational modelling and simulation of molecular systems are becoming indispensable for 21st-century science. However, the size, scale and complexity of realistic materials-biology interactions preclude the application of rigorous, physics-based computational methods like molecular dynamics and quantum chemistry. AI and machine learning are making spectacular inroads into solving these very complex problems. We use a wide range of computational chemistry and AI-based methods to model complex systems and predict their properties. These provide insight into how molecules interact with biology at the molecular level. As these are broadly applicable platform methods, we collaborate with experimental scientists across a wide range of projects, unravelling structure-property relationships problems in materials.

Machine learning for materials and surface science

In collaboration with colleagues from La Trobe we apply advanced informatics and machine learning methods to extract new knowledge from surface analysis methods. We are applying these methods to tissue profiling or tumour samples and to libraries of polymers that are candidate coatings for implantable and indwelling medical devices. In collaboration with colleagues from La Trobe, RMIT, the GetCO₂ CRC and Izmir Institute of Technology, we design catalysts and photo-catalysts for CO₂ reduction, and water splitting photovoltaic and electroactive polymers and perovskites for environment and energy applications and nanomaterials for medical applications.

Next-generation biomaterials

We collaborate on a large University of Nottingham EPSRC project designing new materials for medical applications. We use data from high throughput experiments to build models describing how the chemistry and microtopography of polymeric materials affect cell responses.



Machine learning and deep learning.

(A) Relationships between AI, ML, and deep learning. ML and deep learning are subsets of AI, and the main approaches to realize AI at present.

(B) Main differences between traditional ML and deep learning. Traditional ML needs to generate diverse features before constructing predictive models, while deep learning can directly extract features from raw data. RNN, Recurrent Neural Networks; GAN, Generative Adversarial Networks; CNN, Convolutional Neural Networks; GNN, Graph Neural Networks; RF, Random Forest; MLR, Multiple Linear Regression; SVM, Support Vector Machine; XGBoost, eXtreme Gradient Boosting; kNN, k-Nearest Neighbors

Photo credit: CC BY-SA 4.0 from Yan, Yue, Winkler, Yin, Zhu, Jiang, and Yan, Chem. Rev. 2023, 123, 13, 8575–8637.

Biomarker discovery

We work with colleagues at Sydney and Monash Universities to find biomarkers for colorectal cancer using sparse feature selection and machine learning and to understand how cytokines and essential amino acids drive stem cell fate.

Materials for batteries and corrosion control

Working with collaborators from CSIRO, HZG Hamburg, and RMIT (DP240100753, A\$530k), we use AI and machine learning to design safe organic corrosion inhibitors to address the >\$1Tn market for corrosion control.

International consortium projects

We were part of two EU Horizon 2020 projects on safety by design of nanomaterials: SABYDOMA (€6M.1) and (NanoSolveIT (€6M) and a Marie Skłodowska-Curie project on the use of AI in drug discovery (AIDD, €3.93 M). We have recently joined a new EU H2020 project INSIGHT (Models for the Development and Assessment of High Impact Chemicals and Materials, €4.13 M).

Lab Head: Professor Dave Winkler
(D.Winkler@latrobe.edu.au)

Research Fellow: Dr Jimiama Mosima Mafeni Mase (Nottingham).

Collaborators:

Prof Morgan Alexander; Dr Graziela Figueiredo; Prof Ricky Wildman (Nottingham); Prof Alex Tropsha (UNC Chapel Hill); Prof Nikolai Petrovsky, Dr Sakshi Piplani (Vaxine Pty Ltd, Flinders); Dr Tim Würger; Dr Sviatlana Lamaka; Dr Christian Feiler (Herzberg Institute Hamburg); Dr Ceyda Oksel, (Izmir Institute of Technology); Dr Tu Le; Dr Nas Meftahi; Prof Andrew Christofferson; Prof Rachel Caruso (RMIT); Dr Tony Hughes (CSIRO); Prof Ivan Cole (RMIT); Prof Nico Voelcker; Dr David Rudd (Monash); Prof Michael Morris (Sydney); EU H2020 consortia.

Fields of Study:

Computational chemistry; drug design; AI and machine learning; materials design; complex systems.


Capabilities and Techniques: Mathematical analysis; visualization; and interpretation of complex data.

Translational Opportunities:

Cancer drugs; biomarkers; materials.

Medicinal Inorganic Chemistry and Luminescent Sensors

We use chemical synthesis to prepare new organic and inorganic molecules for medicinal and biological imaging applications. Organic synthetic chemistry is used to prepare ligands for the formation of metal-based coordination compounds with properties optimized for use as medicines, imaging agents, and chemical sensors. Our lab has two main areas of research focus, the first is the development of antibacterial silver and gold-based compounds, which are active against multi-drug resistant bacterial strains. The second research area is the preparation of luminescent and radiolabelled molecules for potential chemical sensor and biological imaging applications. To allow for the selective sensing of carbohydrates, boronic acid-based luminophores have been developed as part of a collaborative project with the Australian fine chemical company Boron Molecular.



Triamine cryptate ligand labelled with the positron emitting radionuclide copper-64.

Silver and gold-based antibacterial agents

Medicinal inorganic chemistry is the development of metal-based compounds as potential medicines. We are working on gold- and silver-based complexes of N-heterocyclic carbene ligands as new antibacterial agents. A series of compounds have been prepared that show excellent activity against both Gram-positive and Gram-negative bacteria and significantly also multi-drug resistant bacterial strains. A noteworthy feature of these compounds is that antibacterial resistance does not develop, whilst resistance is developed against the widely used broad-spectrum antibiotic ciprofloxacin in the same bacterial strains. Current work is focused on evaluating the mechanisms by which these compounds are active and the preparation of targeted gold and silver metallodrugs.

Synthesis and Studies of Luminescent and Electrochemiluminescent Metal Complexes

We are developing luminescent and electrochemiluminescent coordination compounds of, iridium, gold, ruthenium and the lanthanide metals. These compounds are of interest as biological imaging agents and as luminescent chemical sensors. A particular focus is electrochemiluminescence where the luminescent emission is stimulated using electrochemical processes. Current efforts are directed toward tuning the luminescent properties of d-f heterobimetallic arrays (containing d-block and f-block metals) to

provide molecules that are emissive in the infrared region. We are also interested in developing new compounds that can detect and monitor simple sugars and more complex carbohydrates. To achieve this luminescent boronic acid-based molecules that sense carbohydrates have been prepared as part of a collaborative project with the Australian fine chemical company Boron Molecular.

Radiopharmaceutical Imaging Agents for Disease Diagnosis

In this collaborative project with the Australian Nuclear Science and Technology Organization (ANSTO) we are developing new ligands for radiopharmaceutical imaging applications. A range of ligand systems are being used in combination with metallic radionuclides such as technetium-99m and copper-64. Technetium-99m is the most widely used radionuclide in medical imaging and many technetium-99m labelled compounds are currently used to image a range of disease states. As all isotopes of technetium are radioactive, we develop new chemistry using the metal rhenium and an array of rhenium complexes of N-heterocyclic carbene ligands have been prepared. Significantly, our laboratory was the first to successfully label a N-heterocyclic carbene ligand with technetium-99m.

Synthesis of amide-based cryptate and cage molecules

The amide or peptide functional group is critical to life as it provides the linkage between adjacent amino acid residues in proteins. Amides also display interesting coordination chemistry and we have utilized the amide linkage to synthesize new cryptate ligand systems. In this work, a range of cryptate and cage ligand systems incorporating amide groups have been prepared (for example the triamidetriamine cryptate ligand shown in the picture).

Lab Head: Associate Professor Peter Barnard (P.Barnard@latrobe.edu.au)

Lab members: Mr Michael Dewar-Oldis, Mr Quoc Dat Duong, Mr Rahad Rahman, Ms Neha Jangra and Mr Liam Barron.

Fields of Study:

Medicinal Inorganic chemistry; Organic Chemistry; chemical luminescence.

Capabilities and Techniques:

Organic and inorganic chemical synthesis; Medicinal inorganic chemistry; Molecular structural characterization by NMR spectroscopy, mass spectrometry X-ray crystallography.

Translational Opportunities:

Chemical synthesis; peptide synthesis; radiochemistry.


Mitochondrial Proteostasis Lab

Mitochondria are critically important organelles that contribute to a wide range of cellular functions. Unsurprisingly, impaired mitochondrial function is linked to many different diseases including cardiovascular disorders, neurodegeneration and cancer. As mitochondrial proteins and protein complexes are separated from other cellular compartments by a double membrane, specific mechanisms are required for the biogenesis, surveillance, and maintenance of the mitochondrial proteome termed protein homeostasis (proteostasis). A key part of this maintenance is performed by ATP-dependent machines and assembly factors which help protect the organism from disease. Our research focuses on the molecular details of substrate recognition by these machines, from how they recognize protein substrates directly, to how these machines are regulated by specialized components, known as adaptor proteins. Our goal is to conduct fundamental research that improves our understanding of mitochondrial proteostasis in human health and disease.

Complex II assembly

The mitochondrial oxidative phosphorylation (OXPHOS) system fuels the energy demands of most eukaryotes through the generation of the majority of cellular ATP. The OXPHOS system comprises five multi-subunit protein complexes in the mitochondrial inner membrane, termed Complexes I to V. These multi-subunit complexes are composed of redox active cofactors including flavins, iron-sulfur clusters, copper and heme. Assembly of each complex requires assembly factor proteins, which act at several steps, including membrane insertion, subunit association and cofactor incorporation. Mutations in, or the absence of, these assembly factors lead to assembly defects of the various Complexes resulting in mitochondrial dysfunction.

Complex II is composed of four subunits (SDHA, B, C and D). Assembly of these subunits into the final complex requires four dedicated assembly factors (SDHAF1, 2, 3 and 4). Mutations in SDHAF2 affects Complex II assembly, triggering mitochondrial dysfunction and causing cancer. The molecular details and dynamics of Complex II assembly pathway, however,



Structure of human POLDIP2, a novel adaptor protein for the mitochondrial AAA+ protease CLPX. Peptide array illustrating the features of substrate recognition by human CLPX (Photo credit: David Dougan)

remain unclear. Notably, our unpublished data has identified several uncharacterized assembly intermediates. This project will determine the composition of these intermediates and the precise role of the assembly factors within these intermediates.

Molecular dissection of protein degradation pathways in mammalian mitochondria

Our group has a strong track record in the study of regulated protein degradation in various model systems from bacteria to mammalian mitochondria. We have made several ground-breaking findings in the field, including the structural and functional dissection of several essential protein degradation components. We previously identified that the AAA+ (ATPases associated with a variety of cellular activity) protease, LONM, is responsible for the turnover of the Complex II assembly factor, SDHAF2, which forms an intermediate complex with SDHA, *en route* to the final functional complex. Importantly, our unpublished data suggest that the turnover of SDHAF2 is facilitated by a short N-terminal degradation (N-degron) tag composed of two elements one of which is occluded in the SDHA-SDHAF2 assembly intermediate.

This project will dissect the significance of the N-degron, and the mechanism that triggers release of this degron for progression of SDHA into the final complex.

Lab Head: Dr Kaye Truscott

(K.Truscott@latrobe.edu.au)

Lab members: Dr David Dougan

International collaborators:

Prof. Kornelius Zeth (Roskilde University, Denmark); Prof. Kürşad Turgay (MPI, Berlin, Germany)

Fields of Study:

Biochemistry; Mitochondrial Biology; Microbiology, Cell Biology.

Capabilities and Techniques: Biochemistry (protein chemistry, protein structure-function analysis Protein array interactions); Mitochondrial assays, Blue Native PAGE; Bacterial/eukaryotic cell culture.

Translational Opportunities:

Our research is fundamental however it will lead to a better understanding of how chaperones, proteases and assembly factors regulate mitochondrial proteostasis and thus may reveal opportunities for small molecule interventions to prevent late onset mitochondrial diseases.

Molecular Self-Assembly and Nanoarchitecture Group

Our Group studies natural self-assembling systems and uses self-assembly principles to design complex nanostructures. Self-assembly is nature's way of building complex structures from molecular building blocks. Cell membranes, silk fibres and proteins are examples of this process where final structure is the product of a multitude of second order interactions – individually weak, non-covalent bonds between adjacent molecules, the collective effect of which is a strong, stable superstructure. Adapting the self-assembly process to the design of complex nanomaterials from unnatural building blocks requires the study of the natural processes and establishing design rules. This will eventually lead to the development of a "molecular lego" toolbox where the chemical building blocks can be selected to create complex nanostructures.

Phospholipid Self-Assembly

Self-assembled phospholipid bilayers provide the core structure of cell membranes – the physical boundaries of cells and sub-cellular structures that preserve cell integrity while also serving as a platform for life functions related to metabolism, sensing and intercellular communication. Phospholipids, organised into a two-dimensional bilayer, provide the primary membrane structure. We study the formation and physicochemical properties of phospholipid bilayers of various composition, with microscopic and microspectroscopic methods. Our aim is to describe the structural and chemical characteristics of such biomimetic membranes that are deterministic of their collective properties: phase transitions, tension, bending rigidity, as a function of composition and environmental factors. We create artificial biomimetic membranes on arbitrary surfaces to mimic the physiological environment of living cells, for applications in biophysics, while also furthering the fundamental understanding of lipid self-assembly.

Peptide-membrane interactions

Disrupting integrity of cellular membranes underpins many biophysical processes in biology, from immunity to apoptosis and plays many roles in nature, however the mechanism of membrane disruption is not

fully understood. We study membrane disruption by antimicrobial peptides which provide innate immunity against pathogens in most living organisms. They disrupt the cytoplasmic membrane of pathogens, facilitate the efflux of essential ions, and thus disrupt ionic homeostasis. We study the molecular mechanism of these interactions, focusing on identifying the factors contributing to the specificity and selectivity of these peptides towards pathogenic membranes. By studying the role of lipid composition, peptide sequence, the physiological environment and temperature at various stages of the interaction, and the role these factors play in switching between disruptive and non-disruptive interaction pathways, we aim to develop novel peptide-based broad spectrum antibiotics for last resort applications in the clinical setting.

Oligoamide based hierarchical nanosystems and metallosupramolecular frameworks

We developed a unique β 3 oligoamide based self-assembling platform that forms fibrous nanomaterials from helical units, like a molecular LEGO set. These molecules fold into highly stable helices with a pitch of 3.0-3.1 amino acids, hence the side chains align in the larger oligomers. The helical form is stable for short sequences and for a wide variation of amino acid side chain

geometries and chemistries. Metal coordination crosslinking of these molecular fibres creates a unique metallosupramolecular framework, a platform for development into functional nanomaterials. We study the factors affecting the self-assembly of these molecules, working towards implementing multiple self-assembly motifs and chemical "switches" to create either self-spun fibres, two dimensional arrays, or three dimensional metamaterials. The accessible sidechains offer easy pathways of chemical modification of these oligoamides, which we utilize to implement controlled complexity and physicochemical properties.

Lab Head: Professor Adam Mechler, FRSC
(A.Mechler@latrobe.edu.au)

Lab members:


Mr Jose Vilareal-Díaz; Mr Yifan Wang; Ms Zahra Saadatmand; Mr Norton West; Mr Abdalwahab Alshammari.

Fields of Study:

Physical Chemistry; Lipid Self-Assembly; Antimicrobial Peptides; Hierarchical Nanostructured Materials; Surface Chemistry.

Capabilities and Techniques:

Biomimetic solutions for biomedicine; Delivery and effectiveness of antimicrobial peptides and nanoscales.



Self-assembling oligoamides form nano-micro scale hierarchical structures

Multifunctional and Advanced Interfaces Group


Our lab utilizes the physical chemistry of interfaces to engineer innovative materials and surfaces that exhibit multifunctional and responsive properties. Utilizing a multidisciplinary approach which draws on principles from biology, electrochemistry, inorganic chemistry, and geology, we control intermolecular and interfacial interactions and interfacial electric fields to create biosensors, drug delivery, bionic, and nanofabrication technologies. Some of the research activities of the lab include:

Non-fouling optical sensing interfaces

Surface-Enhanced Raman scattering (SERS) is perhaps one of the most versatile transduction mechanisms, with sensitivity to a wide range of analytes and potential for single molecule detection. However, this extreme sensitivity makes the technique exceptionally prone to fouling as signals from any non-specifically adsorbed molecules may also be strongly amplified. Taking advantage of the size selective transport properties of an antiadhesive protein called 'lubricin,' non-fouling, molecular sieving interfaces have been created that can separate small molecule analytes from highly fouling biological fluids (e.g., blood). Using these molecular sieving interfaces, highly sensitive SERS-based optical sensing can be carried out directly in highly fouling media with minimal to no sample processing (extraction, separation, dilution, as is standard practice).

Nanoscale molecularly imprinted conductive polymers


Molecularly imprinted polymers (MIPs) are synthetic polymers with antibody-like binding selectivity to a given molecular target/analyte. Although MIPs have become a powerful tool in preparative/analytical chemistry and sensing, they fall short of their potential due to the high susceptibility to non-specific binding and fouling that currently can only be overcome by extensive sample treatment and processing. This project combines the anti-adhesive protein lubricin with a newly invented 'surface-tethered dopant templating' technique for growing ultra-thin (i.e., < 10 nm), electrically conductive, and optically transparent nanoscale MIPs which exhibit high target binding selectivity. These



Schematic of nanoscale molecularly imprinted conductive polymers



Schematic of non-fouling optical



Nanoimprinted hole array in glass created using pressure solution

non-fouling nanoscale MIPs' can be utilized in highly fouling biological fluids or wastewater to selectively capture target molecules in electrochemical/optical sensor systems or solid-phase extraction applications

Geologically inspired nanofabrication

This project is inspired by 'pressure solution' (PS); a fundamental 'deformation' and mass transfer mechanism in Geology. At its heart, PS describes the enhanced dissolution rate observed when two minerals are pressed together at high pressure in an electrolyte. My lab has recently discovered the electrochemical origins of PS in which an interfacial electric field created when two dissimilarly charged surfaces are pressed together can significantly accelerate the rates of dissolution of certain inorganic materials (e.g., silica, alumina, calcite, etc.) by as much as 1,000,000 (10⁶) times. Because PS only occurs where two surfaces are in 'contact,' PS can be used to selectively remove material underneath a patterned surface or a sharp AFM tip to etch nanostructures using only water and ambient temperatures.

PS enables powerful nanofabrication tools like nanoimprinting and direct write lithography, currently only able to pattern 'soft' polymer substrates, to directly pattern hard and functional inorganic substrate

Lab Head: Associate Professor Wren Greene (W.Greene@latrobe.edu.au)

Lab members:

Ms Luiza Nasciomento
Mr Rahiel Rasool,
Mr Williams Kwaku
Ms Oshin Misquita

Fields of Study:

Physical Chemistry, Electrochemistry, Materials chemistry, Soft Matter, Interfacial Science.

Capabilities and Techniques: Electrochemical methods, Optical Spectroscopy, Atomic Force Microscopy, Surface and Interfacial chemical modification and characterization.

Translational Opportunities:

Sensor and Diagnostics technology, nanofabrication methods.

Muscle Biochemistry Group



The Muscle Biochemistry Laboratory focuses on understanding aspects of muscle function and biochemistry in both health and disease. The laboratory is situated in the LIMS1 building, with full access to all biochemistry facilities. The overall research interest of the laboratory is in the area of skeletal muscle in health and disease. The laboratory focuses on various aspects of skeletal muscle biochemistry, using exercise and disease models in humans, as well as animal models. In particular, the laboratory pioneered and optimised the measurement of proteins in very small samples sizes. This allows proteins to be measured in small segments of individual muscle fibres allowing issues with the heterogeneity of skeletal muscle to be overcome. We also examine movement of proteins following micro-dissection of fibres, allowing quantitative assessment of the redistribution of proteins following various interventions, in particular exercise.

Calpains and MMPs

Calcium dependent proteases calpains, and metalloproteinases (MMPs) have been touted as playing similar roles in muscle. To understand their potential, improving our understanding of their regulation and functional properties in the physiological milieu is crucial. If an individual has an absent or non-functional muscle specific calpain-3, they develop a type of muscular dystrophy (LGMD2A). We have identified that calpain-3 likely plays a role in muscle repair. MMPs play a diverse role in the body, with MMP2 and MMP9 linked to muscle degenerative processes. We use exercise as a manipulation to alter intracellular calcium levels and to investigate how lengthening, or eccentric contractions can affect the activation of calpains and/or MMPs, and to identify their *in vivo* cellular targets.

Glycogen related proteins

By removing the surface membrane of a skeletal muscle fibre by microdissection, we can quantitatively assess crude localisation of proteins in muscle.



H&E staining: healthy (left) & damaged (right) skeletal muscle (Photo credit: Robert Barker)

Our research has revealed that glycogen related proteins are differentially associated with the glycogen granule *in vivo* and also that the important energy sensing molecule, AMPK, along with the glucose transporting protein, GLUT4, are not associated with the glycogen granule. These findings debunk the theory that glycogen utilisation directly affects their function. We continue to explore how these proteins, are involved in skeletal muscle function, in particular in response to exercise and diseases such as type 2 diabetes. Importantly, we are trying to understand what the mechanisms are that result in an improvement in this metabolic disease following exercise interventions.

Mitochondrial dynamics

Mitochondrial content has been described as being reduced with aging, however using our quantitative approaches to protein assessment, we have shown in healthy older adults there is no loss of mitochondrial content or in the ability of mitochondria to adapt to exercise. We identified that an increase in mitochondrial dynamics may be in some way protective to the muscle and overall function.

Lab Head: Professor Robyn M. Murphy (R.Murphy@latrobe.edu.au)

Lab members:

Dr Noni Frankenberg; Dr Barney Frankish; Dr Stefan Wette; Dr Robert Barker; Ms Heidy Flores; Ms Amy Pascoe; Ms Oliva Timson Smith.

Fields of Study:

Biology with Physiology (cellular, animal and biochemistry); Medical Physiology; Human Movement and Sports Science.

Capabilities and Techniques:

Chemidoc imaging (fluorescent, chemiluminescence & UV lights); Leica semi-automated cryostat; LabConco freeze-dryer; Polytron homogeniser for small volumes; Eppendorf refrigerated benchtop microfuge centrifuge; Ultra-sensitive, low volume western blotting.

Translational Opportunities:

Muscle disease diagnostics; exercise physiology; exercise interventions for aged individuals.

Neurodegeneration EV Biology and Biomarker Group


Neurodegenerative diseases, such as Alzheimer's disease (AD) is one of the leading causes of death world-wide. At the early stages of AD, neurons that control memory and thinking are attacked by toxic proteins that causes pre-mature neuronal death. Brain tissue becomes damaged, and patients begin to experience symptoms such as dementia related memory and cognitive impairment – a stage of disease when it is difficult to repair with disease-modifying drugs. Currently, the diagnosis process involves invasive procedures such as brain imaging and cerebrospinal fluid testing but is often performed at the symptomatic stage when damage to the brain has begun. Hence, there is currently an unmet need for an early, convenient, low-invasive blood-based test to diagnose AD. Our group focuses on developing diagnostic tests for neurodegenerative diseases such as Alzheimer's and Parkinson's disease but, also other similar dementia disorders to allow for differential diagnosis.

It's in the blood – Extracellular Vesicles

Exosomes are extracellular vesicles (EVs) that are secreted from cells and tissues where they can then be found circulating throughout the body. They can carry protein and genetic material which have been shown to reflect the host cell. EVs can be isolated from blood making them a potential source of disease biomarkers. Our hypothesis is that EVs secreted from neurons within brain tissue can migrate through the blood brain barrier (BBB) into the blood whereby brain biomarkers are readily detected and reflective of disease occurring the brain, equivalent to a 'liquid biopsy' of the brain. We utilise 'Next-Generation' deep sequencing to identify all the RNA species, in particular microRNA, in EVs isolated from human post-mortem brain tissue and blood of patients with neurodegenerative diseases.

Brain-derived EVs

Historically, it has been challenging to develop biomarkers for brain diseases as neurological biomarkers do not cross the BBB so sampling peripheral whole blood is not reflective of the brain. However, brain-derived EVs (BDEVs) can cross the BBB through specialised transport channels



Testing blood samples for neurodegenerative diseases (Photo credit: James South)

that allow BDEVs to pass the BBB. Our research group has the capability to isolate BDEVs from human brain tissues, a complete game-changer from using cell culture models. We can now investigate the contents and role of EVs isolated from the brain of patients diagnosed with a neurodegenerative disease from an entirely new perspective.

The role of EVs in neurodegeneration We use genomics and proteomics to profile the contents of BDEVs in search for proteins and RNA associated with neurodegenerative diseases. Those we identify are used as potential disease biomarkers but are also further studied in cellular and mice models to understand their role in the pathology of neurodegenerative diseases. We use an array of molecular, cell and protein biology methods to discover biological pathways that are implicated in neurodegenerative diseases and determine whether EVs assist and/or accelerate the disease process.

EV biogenesis of the BBB

Our group seeks to understand the endosomal and non-endosomal pathways of EV biogenesis and release from human brain endothelial cells of the BBB. We will use cellular models of the BBB together with super-resolution microscopy to visualise EVs within endosomal structures and track their

movement across the BBB to the periphery. Unravelling the biogenesis pathways of EVs at the BBB will allow us to manipulate these pathways to deliver therapeutic EVs to the brain to treat neurodegenerative diseases.

LabHead: Dr Lesley Cheng
(L.Cheng@latrobe.edu.au)

Lab members: Ms Robyn Sharples;
Mr Mitch Shambrook; Mr William Phillips;
Mr Christopher Reimann, Mr Priyank Gaijar;
Mr Mihim Fernando.

Fields of Study:

Neurodegeneration, biomarkers, genomics, diagnostics and extracellular vesicles

Capabilities and Techniques:

Cellular, tissue and biological fluid extracellular vesicle purification and characterisation, Molecular diagnostics, Genomic sequencing, proteomics, qRT-PCR/ Digital PCR, automated laboratory instruments, cell culture, cellular imaging

Translational Opportunities:

This research will develop a diagnostic blood test capable of specifically detecting brain-specific disease indicators associated with neuropathological changes in the brain. This would also allow for monitoring decline or improvements during therapeutic treatment. We are currently working with several industry partners within the R&D sector to investigate the use of EVs in therapeutics and diagnostics.

Neurodegeneration and Neurorepair Group


Our laboratory focuses on multiple sclerosis (MS), an autoimmune and neurodegenerative disorder of the central nervous system (CNS). The cause of MS is unknown, but incidence and prevalence of this disease is rising worldwide. Treatment options are unsatisfactory, because of poor understanding of mechanisms underlying tissue destruction, or of the relationship between evolution of these mechanisms and clinical progression. Our goal is to clarify the pathological processes of tissue destruction and the accumulation of neurodegeneration, from the pre-clinical stage. We have developed multiple animal models that mimic facets of MS, as well as approaches including standard histopathological, advanced imaging and molecular techniques. Our long-term aim is to identify primary and targetable mechanisms for early intervention and prevent irreversible neurodegeneration.

Modelling MS

There is no accurate MS model. Instead, experimental paradigms have been developed to study various facets of MS, including virally-induced CNS inflammation (Theiler's murine encephalomyelitis virus model), chemically-induced demyelination (cuprizone, lysophosphatidylcholine) and autoimmune-mediated demyelination (experimental autoimmune encephalomyelitis [EAE]). The EAE model is preferred because it exhibits both inflammation and demyelination. We have developed EAE variants using defined combinations of neuroantigen: mouse strain. This results in clinical progression exhibiting chronic-progressive, chronic-relapsing, or monophasic disease, which can be T cell or B cell-driven. Clinical progression and pathological hallmarks over the disease trajectory have been mapped. We have investigated the earliest timing and mechanisms of neuronal loss and evaluate drug efficacy. Future developments include chemically-induced demyelination models to investigate remyelination strategies.

Mechanisms of neuronal loss

MS inflammation is relatively well understood and treatable with immunomodulatory drugs. However, neurodegeneration is poorly addressed.



Neuron stained with antibody to neurofilament protein (green) targeted by CD3⁺ T cells (red) during the acute phase of EAE. Nuclei are stained with DAPI (blue). (Photo credit: Anton Ramp)

Existing MS therapeutics improve quality of life, but do not arrest the neurodegenerative process or actively promote remyelination. Our lab identified an early and critical role for platelets in neurodegeneration in EAE. We identified platelets in the CNS from the pre-onset stage, throughout the whole CNS and specific platelet targeting of neurons. We also demonstrated platelet targeting of myelin. Behavioural studies have revealed neuropsychological symptoms prior to disease onset. We propose that platelets are the substrate of neurodegeneration and that platelet targeting is a novel strategy for early intervention in MS.

Targeting neuroinflammation

Historically, the inflammatory component of MS has been the focus of drug development, via T and B cell targeting. With respect to T cell targeting, we have demonstrated the efficacy of the S1P analog FTY720 in reducing disease severity. Our studies have revealed high-level complexity responses by the S1P receptor family, whereby each of the receptors expressed in the CNS exhibits differential dose-related and region-specific changes in response to treatment. Using a B cell driven EAE variant, we mapped B cell compartmentalization and showed efficacy of anti-CD20 drugs in disease attenuation. Immunomodulation does not ameliorate neuropsychological symptoms, suggesting that immunomodulation is not neuroprotective.

Platelet targeting in neuroinflammation

In view of the evidence of the early and driving role of platelets in neuroinflammation and the inefficacy of immunomodulatory drugs in promoting neuroprotection, we further investigated the potential of platelet-targeting. Current evidence shows that blocking platelet reactivity is associated with both inhibition of inflammation and restoration of myelination and function. Future studies will elucidate mechanisms underlying the multi-faceted consequences of platelet targeting.

Lab Head: Dr Jacqueline M Orian
(J.Orian@latrobe.edu.au)

Lab members: Ms Jing Ting Vernise Lim (PhD student); Mr Hussam Al-Saraji (Honours Student); Ms Xiaoya Li (Master's student); Ms Sivar Sanjana Iyengar (Master's student).

Fields of Study:

EAE models, multiple sclerosis, myelin biology, neuroimmunology, platelets.

Capabilities and Techniques:

Generation of B and T cell driven EAE variants; Neuroanatomy; Histology; Brightfield and confocal microscopy; Unbiased counting techniques.

Translational Opportunities:

Pre-clinical evaluation of candidate multiple sclerosis and remyelination therapeutics.

Optical Spectroscopy of Atmospheric, Astrochemical and Biological molecules


There is more to light than meets the eye. Light with wavelengths invisible to human sight but detected by sophisticated instruments called spectrometers provide us with a detailed view of the “nanoscopic” molecular world that underpins daily life. We exploit powerful light sources such as infrared, visible and ultraviolet lasers, or the Australian Synchrotron’s infrared beamline to study molecules relevant to pharmaceuticals, atmospheres and astrochemistry. For example, this type of molecular sensing can reveal the shape of neurotransmitter molecules that act as the ‘key’ in receptor ‘locks’ involved with signaling in the brain, the details of how much radiant heat is absorbed by greenhouse gases, the size and temperature of ice nanoparticles like those in high altitude clouds, or the spectral fingerprint patterns that allow molecules in space to be identified through radioastronomy.

Molecules in Space

Life on earth is intrinsically chiral. In the building block molecules such as proteins and sugars, “left-handed” or “right-handed” forms are possible, but only one type is found and the reason for this choice remains unclear. Astrochemistry may well play a role and yet amongst the 200 molecules detected in the interstellar medium outside our solar system to date, propylene oxide is the only one that is chiral. We are undertaking work to increase understanding of its’ spectral properties in the crucial microwave region used for detection. Other work is aimed at finding other chiral molecules in space and identifying the molecules responsible for thousands of unidentified absorption lines measured by radioastronomy.

Atmospheric molecules and their greenhouse absorptions

The absorption of infrared radiation by greenhouse gases in the atmosphere is at the heart of human induced climate change. Some of our research into fluorocarbons has revealed the fine details that may be used to efficiently model the complex pattern of IR absorption within the atmospheric greenhouse window. One of our targets has been dichlorodifluoromethane,




Left and right-handed forms of propylene oxide form patterns of spectral lines like those observed by radio astronomy

commonly known as CFC-12 or refrigerant R12, which despite being present in concentrations of less than one part in a billion has a warming contribution exceeded only by carbon dioxide, methane, and nitrous oxide. Aerosols also play a key role in our atmosphere, affecting the climate both directly through absorption and reflection of light, and indirectly by hosting chemical reactions and influencing cloud formation. Research to investigate the formation, composition and behaviour of aerosols is critical to improve the climate models. A specialised cooling cell with unique capabilities at the Australian synchrotron’s IR beamline enabled us to measure the first far IR spectra of water ice nanoparticles. Such particles as are found in cirrus and mesospheric clouds on earth, and in non-terrestrial environments such as Mars, Titan and the interstellar medium.

Conformational shape of biomolecules

The conformational shape of biological molecules, and their interactions with the surrounding environment including water molecules are critical to their functioning. Laser-based gas phase spectroscopy combined with appropriate computer modelling generates precise structural information on molecules such as neurotransmitters



that provide a rigorous platform for understanding their behaviour and ultimately, rationalizing drug design. The resonant two photon ionisation technique allows electronic and IR spectra to be measured for molecules cooled to a few Kelvin. This results in beautiful, simplified spectra that can be interpreted to reveal the preferred shapes of molecules and how strongly they interact via hydrogen bonding with water.

Lab Head:

Associate Professor Evan Robertson
(E.Robertson@latrobe.edu.au)

Lab members:

Mr Luigi Villani,
Mrs Ishara Peiris,
Mr Kaidan Rolfe.

Fields of Study:

Atmospheres, Astrochemistry, Molecular spectroscopy, Vibrational spectroscopy

Capabilities and Techniques:


Infrared and Raman Spectroscopy, pulsed ns laser systems, ab initio quantum chemistry, rovibrational analysis.

Translational Opportunities:

Gas sensing, applications of Raman spectroscopy extending into many fields.

Peptide Chemical Biology Group

The healthcare costs of antimicrobial resistance (AMR) in Australia are estimated at over \$1 billion a year. Globally, the World Health Organisation predicts that AMR will cost the world up to 100 trillion USD in 2050. Given the emergence and spread of AMR, alternatives to antibiotic drugs are urgently needed. Antimicrobial peptides (AMPs), which form part of a native host defence system, could be a promising solution to this problem. They can have potent and broad-spectrum antimicrobial activity with a reduced tendency to induce resistance. To develop novel alternative antibiotics, our group's research focuses on chemical modifications to enhance their effectiveness and result in significant conformational changes, such as multimerization, bioconjugation and lipidation.



Membrane active peptides targeting bacteria and red blood cells.
(Cover designs from our recent publications)

Antimicrobial peptide-antibiotic conjugates

One solution for contending with multi-drug resistant (MDR) bacteria is the use of combinations of conventional antibiotics. The use of antimicrobial peptides (AMPs) in combination with, or covalently conjugated to, inexpensive antibiotics such as cephalosporin, may provide important specific antibiotics. However, this approach has met with little success due to the difficulties associated with chemically linking dissimilar compounds, particularly the small molecule antibiotics which have limited non-active site availability of functional groups for anchoring. Covalent conjugation of a conventional antibiotic or small molecules to a peptide can be achieved by either total solid phase synthesis using suitably protected and derivatized antibiotic or in solution via a variety of bimolecular reactions. Therefore, in this project, we aim to apply different linker and conjugation approaches to enhance the bioactivity of AMPs and investigate their mode of action.

Antimicrobial peptide multimerization

This project involves the multimerization of AMPs to confer improved properties on other AMPs by enhancing their cationic charge and improving their interaction with

bacterial membranes. The research team has developed a series of new dimeric AMPs to target WHO priority critical Gram-negative bacterial pathogens, such as *A. baumannii* and its multi-drug-resistant strain. They plan to prepare analogues of selected peptides and screen several bifunctional linkers to determine the general applicability of this method.

Dual-function molecules

Chronic wound infections are major complications of Diabetes mellitus and are responsible for significant morbidity and mortality. Over 50% of diabetes patients with Diabetic foot ulcers (DFUs) are estimated to develop diabetic foot infections by a polymicrobial community of microorganisms with wound chronicity. The increasing resistance of pathogens to antibiotics causes a huge clinical burden that places great demands on academic researchers and the pharmaceutical industry for resolution. Previously, we identified two leading AMPs, Pardaxin (1-22) and MSI-78 (4-20) (Clinical Trial Pexiganan derivative), that possess effective antibacterial activity against bacteria, including *Escherichia coli* and *S. aureus*. More recently, our recent study showed that the lipidated chemical

modification enhanced their antibacterial activity against pathogens, but also increased their cytotoxicity. In this project, we will develop novel potent AMPs against DFI pathogens with wound healing properties on innovative chronic wound models.

Lab Head: Dr Wenyi Li
(Wenyi.Li@latrobe.edu.au)

Lab members:
Dr Praveen Praveen;
Ms Claire Lai.

Fields of Study:
Chemical Biology; Peptide chemistry;
Antibiotics; Antimicrobial resistance; mode of actions.

Capabilities and Techniques:
Chemical synthesis for various bioactive peptides, including membrane active peptides and posttranslational modifications; Bioassays for antimicrobial determination in vitro and in vivo of *Galleria Mellonella* infectious model.

Translational Opportunities:
Antibiotics; infectious diseases; drug delivery; diagnosis.


Protease Biology Group

Proteases are involved in multiple biological processes, including the regulation of inflammation. They have been shown to initiate and terminate proinflammatory or anti-inflammatory responses. The dichotomy in the biological roles that proteases exert is essential to drive acute inflammation toward the resolution phase to later return to homeostasis. However, when left unchecked, proteases can also promote inflammatory diseases.

Importantly, proteases play both protective and detrimental roles in inflammatory diseases. Therefore, a greater understanding of proteases coupled with development of strategies to monitor and inhibit their activity is likely to have significant positive impact on human health conditions such as thrombosis, cancer, haemophilia, inflammation, and viral diseases. We are a protein biochemistry laboratory using techniques in molecular biology, protein biochemistry and enzymology to understand how the human body responds to infection and disease by dissecting the activity of enzymes called proteases. We use this mechanistic information to study a crucial part of our immune defenses, the Complement system as well as strategies developed by bacterial pathogens and viruses use in order to avoid killing by complement, which results in infections and disease. In the words of Professor Piet Gros, "The challenge lies in understanding the greater picture. It's about understanding the way in which different molecules work together in a process where everything must happen at exactly the right place and at exactly the right time." The moment when you start to understand how the complex system works is the most gratifying element of this job."

Regulation and control of the complement system in immunity

The complement system is vital in preventing disease caused by infections. The system is also implicated in many diseases associated with excess inflammation. We are studying the classical and mannose-binding lectin (MBL) pathways of complement activation, both of which are associated with inflammatory diseases. These pathways involve the sequential activation of proteins by a



cascade of proteases. Our lab focuses on the initiating proteases of the two pathways: C1r, C1s and the MBL-associated serine proteases (MASPs). Our lab examines how these proteases interact with their target substrates and their regulatory inhibitor, C1-inhibitor. We plan to develop specific protein and peptide inhibitors of the different proteases to determine their roles in diseases.

The enemy within: targeting the viral entry facilitator of SARS-CoV2

The COVID-19 pandemic caused by SARS-CoV-2 has posed an enormous challenge to public health, and the threat still has a significant impact on humanity. The molecular properties of SARS-CoV-2 infection have been quickly elucidated, paving the way to therapeutics, vaccine development, and other medical interventions. Despite this progress, the detailed molecular mechanism of SARS-CoV-2 infection remains elusive. Given virus invasion of cells is a determining factor for virulence, understanding the viral entry process can be a mainstay in controlling newly emerged viruses. TMPRSS2 is a type II transmembrane serine proteases (TTSP) that has been shown to be crucial for host cell viral entry and spread of SARS-CoV-2, as well as SARS-CoV, MERS-CoV, and influenza A viruses. Our team has extensive expertise in the study of serine proteases involved in infection-driven inflammation and

intracellular host responses. We will use our cross-disciplinary expertise to examine the proteolytic signature of viral infectivity by examining the enzymatic function and structure of TMPRSS2. We will then use this knowledge to dismantle the host cell machinery that enables the virus to infect the host cell and spread from one cell to another. We anticipate that this work will provide mechanistic insights into precisely how TMPRSS2 acts as a host factor that is essential for the infectivity of SARS-CoV-2. Many medically significant viruses require host cell proteolytic activation to result in functional infectious particles, making the unravelling of the infection process by targeting host-derived machinery in this study highly relevant to both basic science and potential therapeutic applications.

Lab Head: Dr Lakshmi Wijeyewickrema (L.Wijeyewickrema@latrobe.edu.au)

Lab members: Professor Rob Pike; Ms Jing Pang

Fields of Study: Innate Immunity; Enzymes; Enzyme inhibitors; Coagulation; Viral Entry.

Capabilities and Techniques: Protein production; Enzyme kinetics; Protein Biochemistry.


Translational Opportunities: Development of specific inhibitors.

Structural Biology and Bacterial Pathogenesis Group

Antimicrobial resistance (AMR) is recognised by the World Health Organisation (WHO) as a critical threat to human health. The overuse of antibiotics has led to AMR bacteria (superbugs), which are now widespread in hospitals around the world. In 2019, AMR infections were associated with 4.98 million deaths worldwide, placing resistant bacteria among the leading causes of death for people of all ages. Meanwhile, the antibiotics development pipeline is near-empty which demands for the urgent development of new molecules to fight bacterial infections. Our research examines the molecular mechanisms underlying bacterial infections. Our multidisciplinary approach combines X-ray crystallography, molecular biology, biochemistry and biophysics to investigate the structure-function relationships in proteins involved in bacterial pathogenesis. Our work provides new knowledge on therapeutically important microbial proteins and the tools to guide the development of new antimicrobial classes.

Structure, Function and Mechanism of action of bacterial virulence proteins Bacterial pathogens deploy an arsenal of virulence factors to establish infection and cause disease. Autotransporter proteins, the largest group of outer membrane and secreted proteins in bacteria are involved in host cell adhesion and toxicity, and promote the formation of aggregated communities and biofilms, which are critical strategies bacteria use to resist the host immune response and antibiotics. Autotransporters are also highly immunogenic and are integral components of human vaccines. We study how autotransporter proteins promote disease and allow bacterial survival by forming protective biofilms. We focus on important therapeutic autotransporters and investigate their mode of action at atomic resolution, as well as whether inhibition of autotransporter function prevents infection.

How bacterial pathogens make toxins and antibiotic resistance enzymes Bacteria produce folding enzymes (foldases) necessary to produce functional virulence factors. These include the Dsb family of proteins, which catalyse a key step in the protein-folding pathway, the introduction of disulfide bonds. Mutants defective in the Dsb pathways have reduced



fitness and pathogenic potential. Our team, in collaboration with national researchers, is leading the structural-functional characterisation of these key bacterial enzymes. We dissect the molecular mechanisms through which some bacteria catalyse the folding of proteins involved in host infection and bacterial resistance. Our studies provide structural information to guide inhibitor development.

Harnessing structural information to drive the discovery of antimicrobials The increase of antimicrobial resistant infections highlights the critical need for new therapeutics. We are developing novel antibiotics that target virulence rather than viability. Disarming rather than directly killing bacteria is a new paradigm for antibacterial therapy that will lead to lower resistance rates than current antibiotics. We are developing small drug-like molecules or antibody inhibitors against key enzymes, secreted toxins and biofilm forming proteins from multidrug-resistant *Enterobacteriaceae*. For example, we have developed monoclonal antibody-based inhibitors that bind to specific autotransporter proteins and prevent the formation of bacterial biofilms. We have patent-protected this novel technology, which represents an entirely new strategy for targeting bacterial biofilms and meets all four

innovation criteria defined by the World Health Organisation (WHO) - new mode of action, no cross-resistance to antibiotics, new target and new chemical class.

Lab Head: Associate Professor Begoña Heras (B.Heras@latrobe.edu.au)

Lab members: Dr Jason Paxman (Snr Postdoc); Dr Tony Wang (Adjunct); Dr Pramod Subedi (Adjunct); Dr Lilian Hor (Adjunct); Mr Carlos Santos; Ms Akila Pilapitya; Ms Kaitlin Clarke; Ms Taylor Cunliffe; Ms Stephanie Penning.

Fields of Study: Structural biology; Biochemistry; Microbiology; Host-pathogen interactions.

Capabilities and Techniques: Structural biology (X-ray crystallography, SAXS); Biochemistry (protein chemistry, enzyme kinetics, redox biochemistry, stopped-flow assays, enzyme kinetics); Biophysics (Analytical Ultracentrifugation, CD spectroscopy, SPR); Microbial assays (biofilm and aggregation assays, motility, in vitro susceptibility testing.); Structure-based drug design and computational biology (molecular docking); Bacterial/eukaryotic cell culture; Microscopy.

Translational Opportunities: Develop new antibiotic classes to counteract antimicrobial resistant infections; develop antimicrobials against critical priority pathogens recognised by WHO; develop small molecules and biologics targeting virulence.

Translational Biology Group


Our group studies the molecular basis of various inflammatory diseases and we aim to develop therapies to combat these. Inflammation is essential in alerting the immune system to infection or tissue injury so that the host's white blood cells can quickly locate and combat the pathogen or engage in tissue repair. This response is tightly controlled, with inflammation waning after infection/injury is resolved – returning to basal levels with the host's white blood cells following suit. An uncontrolled inflammatory response leads to various diseases such as multiple organ failure in sepsis, various fibrotic diseases and autoimmune diseases (e.g. psoriasis, systemic lupus erythematosus and inflammatory bowel disease etc). Our lab has identified upstream cell surface receptors regulating these diseases and we aim to develop therapies by blocking receptor activation.

Trem14 receptor and innate immune memory

We have identified Trem14 receptor as the master regulator of inflammation during polymicrobial sepsis. Genetic ablation of this receptor in mice offers almost absolute protection from sepsis-mediated inflammatory pathology and immune cell apoptosis. Our findings suggest that ablating this receptor can induce neutrophil memory after exposure to sepsis, which enables the mice to combat blood-born *Candida* infection. This protection can last up to a month despite neutrophils lasting only 24 hours in the blood, and suggests neutrophil memory, which is a new concept. We have evidence this memory is imparted through epigenetic modification in the bone marrow compartment and we are studying the underlying mechanism using ChIP-Seq and single cell RNASeq analyses.

Developing biologicals against Trem14 receptor

We identified the Trem14 receptor in a genome wide CRISPR screening of mice undergoing polymicrobial sepsis and developed an *in vitro* assay to test the functionality of this receptor family. We are also developing humanized mouse models expressing the human receptor to enable us to study the function of this protein in an *in vivo* system and allow testing *in vivo* of any biologicals that we develop (i.e., monoclonal antibodies (mAbs), i-Bodies, shark antibodies and human Fabs) to treat sepsis, psoriasis, SLE and IBD.



Inflammation in various structures

Single domain antibodies against fibrosis and inflammatory diseases

Shark antibodies (VNARs) are a subset of antibody-like molecules found in sharks and rays. Some VNARs have been shown to possess a long CDR3 loop, which is much larger than those of human and murine antibodies. This extended CDR3 loop is ideal for penetrating cleft-type epitopes such as enzyme active sites and ligand binding sites of surface receptors that are otherwise inaccessible to conventional antibodies. We created a humanized version of these antibodies, called i-bodies, and identified binders from this library that bind to the chemokine receptor CXCR4. This molecule is up regulated in many cancer cells and is expressed in organs that have developed fibrosis and other inflammatory diseases. The i-body that binds to CXCR4 (AD-214) can bind to and block the migration of inflammatory cells towards the site of inflammation thereby preventing the development of fibrosis in animal models of pulmonary fibrosis, kidney fibrosis and eye fibrosis in macular degeneration. The biotechnology company, AdAlta has completed manufacturing, toxicity, and a Phase 1 human clinical trial with AD-214. AD-214 was shown to be safe and is currently progressing towards the clinic for Idiopathic Pulmonary Fibrosis. We are examining how AD-214 can block the molecular signaling pathways of CXCR4 and prevents inflammation and fibrosis.

Single domain antibodies in malaria

The *Plasmodium falciparum* parasite causes severe malaria in humans. We identified VNARs and i-bodies that block invasion of malaria into host erythrocytes. The structural complex of one of these VNARs and its target AMA1, revealed that the long loop of the VNAR can penetrate a hydrophobic trough on this protein and block the function so the parasite is unable to invade the red blood cell. We identified i-bodies that bind to AMA1 from all *P. falciparum* strains and have shown that some can block parasitic invasion into blood cells. We are collaborating with colleagues to develop these i-bodies as potential therapies to understand the molecular tricks that the malaria parasite uses to invade blood cells.

Lab Heads: Associate Professor Hamsa Puthalakath (H.Puthalakath@latrobe.edu.au) and Professor Michael Foley

Emeritus: Professor Robin Anders

Lab members: Dr Dimuthu Angage, Dr Tony Wang, Mr Hussam al Siraji, Mr Corey Pollock and Ms Nicki Badii.

Fields of Study:

Inflammation; Innate immunity; Fibrosis; Antibody development.

Capabilities and Techniques:

CRISPR gene editing; mouse models; i-Body/ Fab library panning; disease models

Translational Opportunities:

Developing biologicals against human inflammatory pathologies.

Vascular Cell Death, Clearance and Inflammation Group

Billions of cells in the body die every day as part of normal cellular turnover and in disease. The removal of dying cells by phagocytes, known as 'efferocytosis', is a critical biological process that maintains tissue homeostasis through replenishing dying cells and limiting inflammation.

Our team aims to understand how dying cells within the blood vessels communicate with surrounding tissue and to elucidate the importance of cell clearance by vascular cells, both in the context of normal vessel maintenance and to promote vessel repair following injury or disease. We have a special interest in how vascular cells participate in efferocytosis during inflammatory vascular diseases such as atherosclerosis and hope to identify novel therapeutic targets that may limit plaque progression.



Targeting efferocytosis in atherosclerosis

Atherosclerotic plaques that block arteries can lead to life-threatening clinical events such as heart attack and stroke. During atherosclerosis, dead cell removal (efferocytosis) is impaired and contributes to plaque growth, although there are currently no treatments that boost dead cell removal in plaques. Our team has recently found that increasing the way cells break apart or 'fragment' when they die enhances their ability to be removed by phagocytes. Using complimentary genetic and pharmacological approaches including a genetic mouse model of enhanced dying cell fragmentation and FDA-approved drugs that promote dying cell fragmentation, our team aims to examine the impact of boosting dead cell removal on plaque growth during atherosclerosis.

Endothelial cell efferocytosis

Efferocytosis is a critical process that prevents inflammation and replenishes damaged cells. Although efferocytosis is a well-described function of certain cell types (e.g. macrophages), the role of vascular endothelial cells that line the blood vessels in mediating efferocytosis is currently unknown. Our team aims to define the mechanisms and functions of efferocytosis by vascular endothelial cells using cell-based methods as well as in vivo transgenic animal models of cell clearance including zebrafish and mouse. Our research aims to determine the importance of endothelial cell-mediated efferocytosis and the impact of enhancing this process in diseases characterised by vessel damage, such as diabetes.

Lab Head: Dr Amy Baxter
(A.Baxter@latrobe.edu.au)

Lab members:
Donia Abeid
Cailin Vella.

Fields of Study:

Cell death and clearance biology; vascular biology; cardiovascular disease; extracellular vesicles.

Capabilities and Techniques:

Tissue culture and mammalian cell death and clearance assays; protein biochemistry, molecular biology (e.g. qPCR, RNAseq); zebrafish and mouse models of disease; confocal, spinning disk and IVIS imaging; extracellular vesicles isolation and characterisation.

Translational Opportunities:

Through identifying novel therapeutic targets of in our pre-clinical models, we aim to establish a drug discovery platform that will lead to the development of novel compounds to treat cardiovascular diseases.

Vascular Therapeutics and Regeneration Group


Blood and lymphatic vessels play important physiological functions in our body and are dysregulated in various human diseases. Excessive blood or lymphatic vessel growth leads to vascular anomaly including lymphatic malformations and increases the risk of cancer metastasis by providing pathways for cancer cells to disseminate. Inversely, lack of lymphatic vessel growth/regeneration results in primary or secondary lymphoedema, a major burden for post-cancer surgical/radiation therapy patients. Our group uses the optically transparent zebrafish model to identify vascular modulatory therapeutics that could be used to treat these diseases. We also characterize dynamic signaling mechanisms that drive vascular maintenance, regeneration and pathologies using various biosensor zebrafish transgenics and zebrafish disease models to decipher targetable therapeutic targets for these diseases.

Pro-lymphangiogenic therapeutics

Lymphoedema is a disease associated with excessive tissue swelling. When left untreated lymphoedema symptoms can worsen, leading to decreased mobility, chronic pain and increased risk of potentially lethal infection. Primary lymphoedema (caused by genetic mutation) is currently incurable, and treatment options available only alleviate the symptoms. While several surgical treatment options exist for secondary lymphoedema (acquired through lymphatic trauma), data on patient outcomes are still limited, as surgical approaches are highly personalised to each case and outcomes can be highly unpredictable. Using cutting-edge methodologies in zebrafish, we seek to understand the mechanisms that drive/inhibit lymphatic regeneration to reveal therapeutic targets for stimulating lymphatic regeneration. We are also using various in vivo (zebrafish) screening approaches to identify pro-lymphangiogenic therapies that will be tested on our zebrafish lymphoedema models.

Anti-(lymph)angiogenic therapeutics

We have a strong track record of using the zebrafish model to identify novel mechanisms of (lymph)angiogenesis. These mechanisms could be targeted to inhibit pathological lymphatic/blood vessel growth



Endothelial cell nucleus in zebrafish blood and lymphatic vessels. (Photo credit: Kazu Okuda)

in human diseases. We are particularly interested in RNA helicase DDX21, which we recently found to be selectively required for lymphatic development in zebrafish. We are now investigating the mechanisms that drive this selectivity. We are also conducting drug screens in zebrafish to identify promising anti-(lymph)angiogenic small molecules. We have already identified several promising leads including 3, 4-Difluorobenzocurcumin and Canthin-6-one. The mechanism of action of these leads will be elucidated to potentially identify novel therapeutic targets for anti-(lymph)angiogenic therapy. We are also testing whether these leads could be novel therapeutics for lymphatic malformations and cancer.

Understanding dynamic signaling activity in blood and lymphatic vessels

The optical transparency of zebrafish embryos/larvae allows live-imaging of developing/functional/regenerative/pathological blood and lymphatic vessels at unprecedented resolution. We have developed zebrafish biosensor transgenic lines that enable real-time visualization of important signaling activities in blood and/or lymphatic endothelial cells such as ribosome

biogenesis and Erk signaling. We are developing new biosensor zebrafish transgenics that enable visualization/quantification of various signalling activities in endothelial cells. We will use these biosensor transgenics to elucidate dynamic mechanisms that drive vascular development, maintenance, and regeneration.

Lab Head: Dr Kazuhide Shaun Okuda
(K.Okuda@latrobe.edu.au)

Lab members: Dr Srdjan Boskovic;
Ms Valeria Impicciche; Mr Bhavya Viradia;
Ms Ira Ghosh; Ms Pooja Shree Rnagaraj; Ms
Linda Jiabao Woo.

Fields of Study:

Vascular Biology; Drug discovery;
Regeneration; Disease modeling.

Capabilities and Techniques:

Zebrafish research; High resolution/speed live-imaging and analysis; Drug screening and characterisation; CRISPR gene editing; Disease modeling; mRNA technology research.

Translational Opportunities:

Vascular modulatory therapeutics we identify could be used to treat human diseases such as lymphatic malformations, lymphoedema and cancer.

Viral & Structural Immunology Group

We focus on how to combat viral infections. Viruses are part of day-to-day encounters that our immune system needs to deal with. How the immune system “sees”, recognises and eliminates viral infection is not fully understood. Indeed, viruses can mutate and escape the immune system surveillance. If we are to develop better vaccine and drugs, it is essential to understand the mechanism of viral recognition and escape prior to this. Our laboratory combines both the cellular and molecular approaches to understand the immune system. Our goal is to deepen our current understanding of T cell activation and recognition mechanism, especially in the context of viral infections such as SARS-CoV-2, influenza and HIV.

Viral Immunology

Our lab is focused on understanding infections by viruses that are a health burden. Aiming to understand why some of us are at higher risk of developing severe infection due to those viruses, while other seems to be able to handle the virus and have an immune system allowing them to control the infection.

COVID-19 disease

We study COVID-19 disease to understand the immune response to SARS-CoV-2 and its variants. We work in collaboration with other teams in Australia and overseas to fully dissect the T cell, B cell and Antibody responses toward the virus. We aim to map and characterise in depth SARS-CoV-2 peptides able to stimulate T cells in better understand the progression of the disease, the role of T cell in COVID-19. This information can help anticipate or predict which mutation will be an issue for T cell recognition, as well as quickly assessing the impact on the immune system, and immune protection, that new SARS-CoV-2 variants might have. This also will help us understand the risk factor worsening the COVID-19 disease, if some marker can be used to predict the evolution of the disease. We also study the level of protection from the vaccines to help inform the need for future booster shot. Our lab has discovered the first genetic link associated with the lack of symptom in COVID-19 published in *Nature*.



The Gras Lab

Influenza disease

Influenza viruses cause significant morbidity and mortality worldwide. Although a vaccine is available, it primarily induces a humoral response (antibody) and requires updating annually. Also, the vaccine provides protection if the predicted strains match the circulating strains, but sometimes the virus mutate away from the prediction and the vaccine will have minimal benefit. Our aim is to develop a universal influenza vaccine that could provide protection against distinct influenza strains. This will allow a one-shot vaccine to be developed, instead of having the “jab” every year.

AIDs disease

While antiretroviral therapy (ART) has dramatically improved the health of HIV-infected individuals, comorbidities associated with persisting inflammation have emerged as complications. It is imperative to develop new treatments (and ideally, a vaccine) for this virus. Our work focuses on individuals known to control HIV infection and/or delay disease progression. They have strong T cell responses and understanding the mechanism behind it is central for informing therapeutic or vaccine development against HIV. We aim to understand how HIV controllers T cells

are protective, their functional but also molecular features, which could lead to new therapeutic avenues.

Lab Head: Professor Stephanie Gras
(S.Gras@latrobe.edu.au)

Lab members:

Dr Emma Grant, ARC DECRA fellow; Dr Dimitra Chatzileontiadou; Dr Janesha Maddugage, Dr Anurag Adhikari; Mr Dhilshan Jayasinghe; Mr Lawton Murolo; Mr Samuel Liwei Leong; Ms You Min Han; Ms Georgia Dow, Ms Jamie Tuebo.

Lab adjuncts:

Dr Christopher Szeto; Dr Andrea Nguyen.

Fields of Study:

Cellular Immunology; viral disease (e.g. influenza, SARS-CoV-2, HIV); T cell activation; epitope presentation; Structural biology.

Capabilities and Techniques:

X-ray crystallography; biochemistry; protein interaction; human samples biobank; cellular assay; immunology; single cell sequencing; flow cytometry.

Translational Opportunities:

T cell engineering; biomarker identification; risk factor of disease; drug design and anti-viral development.

Web site: www.graslab.com.au

About La Trobe University

Our Mission

Advancing knowledge and learning to shape the future of our students and communities.

Our Vision

To promote positive change and address the major issues of our time through being connected, inclusive and excellent.

Our Values

Our early reputation as a radical and challenging institution continues to influence the way we enrich the experience of our students and engage with our partners and communities.

We were founded half a century ago to broaden participation in higher education in Melbourne's north and, later, in regional Victoria. We have succeeded for many thousands of students who would otherwise have been excluded from the opportunities provided by a university education.

We continue to support access, diversity and inclusivity while undertaking world-class research that aims to address the global forces shaping our world and make a difference to some of the world's most pressing problems, including climate change, securing food, water and the environment, building healthy communities, and creating a more just and sustainable future. This approach is based on our values of:

- inclusiveness, diversity, equity and social justice
- pursuing excellence and sustainability in everything we do
- championing our local communities in Melbourne's north and regional Victoria
- being willing to innovate and disrupt the traditional way of doing things.

Of all Australian universities, we are the most successful at combining accessibility and excellence, and have become a place where social inclusion and globally-recognised excellence come together for the benefit of our students, our staff and our communities.

Our academics and researchers achieve national and international recognition, our public intellectuals demonstrate an enduring social conscience and influence, and our alumni achieve extraordinary success and impact in government, industry and not for profit organisations.

We strive to be exemplars for the sector in our commitment to gender equity and to inclusivity for marginalised groups; and we work with indigenous peoples and organisations to support their social, cultural and economic aspirations.

We embrace sustainable practices across all our campuses because we are committed to improving environmental, social and economic outcomes for our communities.

We contribute to economic development for our local communities, and our future activity will increasingly be international as we become a globally connected university in everything we do.

Our Culture

La Trobe Cultural Qualities

Our cultural qualities underpin everything we do. As we work towards realising the strategic goals of the University we strive to work in a way which is aligned to our four cultural qualities:



Connected

- We are Connected: Connecting the students and communities we serve to the world outside



Innovative

- We are Innovative: Tackling the big issues of our time to transform the lives of our students and society



Accountable

- We are Accountable: Striving for excellence in everything we do. Holding each other to account, and working the highest standards



Care

- We Care: We care about what we do and why we do it, because we believe in the power of education and research to transform lives and global society.

About Victoria and Melbourne

Experience Melbourne

Melbourne is the capital of the state of Victoria, and Australia's second largest city. It's a multicultural hub with 4.5 million people from over 153 countries. It's one of the world's best sporting cities, and is Australia's art and culture capital. Melbourne is a safe, well-serviced city in which to live. The main campus of the University at Bundoora is close to many world class hospitals, schools, research centres, shopping centres, bike paths and parklands. Melbournians enjoy, affordable healthcare, world-class education, reliable infrastructure, business opportunities and a healthy environment. In Melbourne you'll find just about every cuisine: French, Italian, Spanish, Greek, Chinese, Malaysian, Indian, Thai, Japanese, Moroccan and lots more. Melbourne has over 100 art galleries as well as theatres, international and local opera, ballet, comedy and live music.

Each year Melbourne hosts major international sporting events like the Australian Open Grand Slam tennis tournament, the Formula One Grand Prix, the Rip Curl Pro surfing championship, the Australian Masters golf tournament, the Melbourne Cup and the Grand Final of Australian Rules Football. As well as over 2500 festivals and events including the Melbourne International Arts Festival, Melbourne International Film Festival, Melbourne International Comedy Festival and the Melbourne Spring Racing Carnival.

Find out more: <https://liveinmelbourne.vic.gov.au/discover>



La Trobe University Campuses in Australia

Each of our seven campuses (Melbourne, Albury-Wodonga, City, Bendigo, Shepparton, Mildura and Sydney) is a unique expression of place, people and history that play an important role in social, cultural and economic life. We are located in Victoria's major regional cities, creating a unique network of research, industry and innovation expertise that can be accessed across the state.



Victoria: The Garden State

Victoria has many notable gardens and 36 national parks covering two and a half million hectares. Victoria's many attractions include the Great Ocean Road, (stunning coastal views and the world-famous Twelve Apostles), the Grampians and the High Country.

Find out more: visitvictoria.com

Melbourne Campus

La Trobe's Melbourne Campus has 27,000+ students and is surrounded by bushland. Students from across the world take advantage of state-of-the-art facilities, including our AgriBio Research Centre, the La Trobe Institute for Molecular Science and our very own Wildlife Sanctuary.

Albury-Wodonga Campus

La Trobe's Albury-Wodonga Campus has 800+ students and is home to our leading regional research centre, the Centre for Freshwater Ecosystems which focuses on water science and policy of the Murray-Darling basin. Here, undergraduate students work alongside Honours and research students on local issues.

